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ABSTRACT 
 
 
 Laboratory animals are often subjected to various painful surgical procedures 
such as laparotomy, thoracotomy or orthopedic procedures as well as non-surgical 
procedures such as the induction of arthritis.  Any procedure that causes pain in humans 
is assumed to cause pain in animals too. It is the ethical obligation of all research 
personnel to reduce or preferably eliminate pain and distress by using analgesics.  
Furthermore, the Institutional Animal Care and Use Committee (IACUC) requires that 
appropriate anesthetics and/or analgesics must be used to minimize or eliminate pain and 
distress for animals undergoing painful procedures.  
 
The oral administration route is the most convenient delivery method for humans. 
However, using the oral administration route for rodents, such as putting an analgesic in 
the water, runs the risk of inaccurate dosing and that of degradation due to hydrolysis. 
Therefore methods for analgesic delivery to rodents are primarily limited to parenteral 
rather than oral delivery. 
 
Rodents are the most universally used laboratory animals and are often subjected 
to research involving painful procedures. A survey of current literature indicates that 
buprenorphine is the most widely used narcotic analgesic for rodents because of its 
excellent analgesic activity and long duration of action. The Formulary for Laboratory 
Animals lists the buprenorphine dose for rats as 0.05 mg/kg (SC, tid, qid). Other 
referenced buprenorphine doses for rats vary widely (0.01-0.05 mg/kg, SC/IV, tid, bid) 
and require multiple administrations. The recommended dose of buprenorphine for mice 
following laparotomy is 0.05 to 0.1 mg/kg, subcutaneously (SC) twice a day. Referenced 
buprenorphine doses for maintaining analgesia in mice vary widely (0.05-2.5 mg/kg, SC, 
IV) and repeated administration is required. However, no sustained-release analgesic 
product for rodents was available when we started the project in 2008. Therefore, in order 
to reduce the stress of frequent handling and injection as well as improve the well-being 
of research animals, the first objective of this project was to develop a long-acting 
sustained release formulation of buprenorphine which is capable of maintaining analgesia 
in rats and mice for 3 to 5 days following a single subcutaneous administration. 
 
Current United States Pharmacopeia (USP) apparatus for in vitro drug release 
testing was designed mainly for oral and transdermal products. In contrast, there are no 
standard regulatory methods for parenteral sustained release products at present. As 
regards to quality control as well as formulation development purposes, it is still highly 
desirable to develop a suitable in vitro release model for parenteral products with the 
characters of Level A In Vitro-In Vivo Correlation (IVIVC) and elaborate drug release 
mechanism. So far there is no successful in vitro dissolution method with the character of 
Level A IVIVC exists at present for parenteral oily formations. Only a few publications 
stated in vitro in vivo correction for parenteral product, but they were developed from 
only one particular formulation. In addition, for most examples in which IVIVC was 
stated for parenterals, the mathematical models that described the drug release had not 
been provided. Therefore, the second objective of this study was to (1) design and 
 vi 
develop a new dissolution model with the character of Level A IVIVC for oily 
formulations, and (2) develop a mathematical equation to describe the drug release 
mechanism from the in vitro model. In general, it is accepted that the process of 
development and validation of IVVIC for parenterals could follow the same principles as 
modified release (MR) oral products. The principles of FDA IVIVC MR guidance for 
oral products were used to develop and validate level A IVIVC for parenterals in this 
study.  
 
In order to develop sustained release analgesic formulations, nine hydrophobic 
vehicles, which have been used in the pharmaceutical products, were selected based on 
clogP values. Solubility and short-term stability studies were performed and six vehicles 
were selected as candidates according to the results.  Since there is no validated in vitro 
dissolution model for sustained release parenterals at present, a new in vitro dissolution 
model were designed based on the in vivo drug absorption mechanism after subcutaneous 
injection. In addition, a mathematical equation was proposed and validated to describe 
the drug release from this dissolution system. In order to apply this dissolution model to 
screen the parenteral formulations in vitro, Level A IVIVC study were performed. In-
vivo release of buprenorphine from two different oily solutions was performed after 
subcutaneous administration in rats. Loo-Reigelman method was used to deconvolute 
plasma data. The mathematical equation, proposed to describe the in vitro drug release 
profiles, was also corresponded well with the in-vivo deconvolution data for the tested 
formulations (R2>0.99). Good linear correlations (R2 > 0.99) were also obtained between 
the mean fraction of drug absorbed and the mean percentage of drug dissolved. Internal 
predictability showed that absolute predictive error (%PE) of Cmax and AUC were 4.9% 
and 0.9%, 12.6% and 3.4% for the tested formulations, respectively. External 
predictability showed that absolute predictive error (%PE) of Cmax and AUC were 
11.9% and 1.1%. This new designed in vitro dissolution apparatus was used to screen six 
oily vehicles and TBC was selected. After subcutaneous injection of TBC formulation at 
the dose of 1.5 mg/Kg in rats, 55% of maximum possible effect (MPE) analgesia can be 
maintained for 3 days and 20% MPE for 5 days in conventional tail flick model. The 
same formulation was tested in mice at the dose of 2.2 mg/Kg which can maintain more 
than 30% MPE analgesia for 3 days and at the dose of 8.9 mg/Kg which can keep at least 
47% MPE analgesia for 4 days.  
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CHAPTER 1.    INTRODUCTION 
 
 
1.1. Buprenorphine 
 
 
1.1.1. Description 
 
Buprenorphine is a μ-opioid receptor partial agonist and a κ-opioid receptor 
antagonist listed in Schedule III of the Controlled Substances Act.1 It is a semi-synthetic 
opioid derived from thebaine.2 It was first marketed in the 1980s by Reckitt & Colman 
(now Reckitt Benckiser) as an analgesic. The chemical structure of buprenorphine 
(Figure 1-1) resembles that of morphine, but it contains a cyclopropylmethyl group on 
the nitrogen atom. Buprenorphine base is a white or almost white powder and is slightly 
soluble in water, freely soluble in acetone, soluble in methanol and ether and slightly 
soluble in cyclohexane. The pKa values of buprenorphine are 8.5 and 10.0.3  
 
 
1.1.2. Current commercial dosage forms of buprenorphine in human 
 
Current commercially marketed products of buprenorphine in humans include 
Buprenex injection, Suboxone tablet, Subutex tablet, Suboxone film, Transtec ER patch, 
Butrans ER patch, Norspan ER patch and Probuphine implant (Table 1-1). 
 
Buprenex1 is a parenteral opioid analgesic intended for intravenous or 
intramuscular  administration for the relief of moderate to severe pain. Each mL of 
Buprenex injection contains 0.324 mg buprenorphine hydrochloride (equivalent to 0.3 mg 
buprenorphine), 50 mg anhydrous dextrose, water for injection and HCl to adjust pH. 
 
Both Subutex1 tablet and Suboxone1 tablet are indicated for the treatment of 
opioid dependence by sublingual administration because of the poor oral bioavailability 
of buprenorphine. Subutex contains only buprenorphine hydrochloride with other 
excipients, lactose, mannitol, cornstarch, povidone K30, citric acid, sodium citrate and 
magnesium stearate. Suboxone contains an additional ingredient, naloxone, with other 
excipients, including lactose, mannitol, cornstarch, povidone K30, citric acid, sodium 
citrate, FD&C Yellow No.6 color, magnesium stearate, acesulfame K sweetener and a 
lemon/lime flavor. Naloxone is an opioid antagonist and is used in Suboxone tablet to 
deter the abuse of tablets by intravenous injection. Subutex and Suboxone are both 
available in 2 mg and 8 mg sublingual dosages. 
 
Suboxone1 is also approved by FDA on August 30, 2010 as a sublingual film in 
both the 2 mg/0.5 mg and 8 mg/2 mg dosages (buprenorphine/Naloxone). Reckitt 
Benckiser Pharmaceuticals claimed that the film has some advantages over the traditional 
tablet including dissolving faster, better taste, adhering to the oral mucosa under the 
tongue and preventing it from being swallowed or falling out. 
 
 2 
 
 
 
Molecular weight:  467.6 
Empirical formula:   C29H41NO4. 
CAS Number:  52485-79-7 
Chemical name:  (2s)-2-[17-cyclopropylmethyl)-4, 5α-epoxy-3-hydroxy-6-methoxy-
6α, 14 -ethano-14α -morphinan-7α -yl]-3,3-dimethylbutan-2-ol 
 
 
Figure 1-1. Chemical structure, molecular weight, empirical formula, CAS 
Number and chemical name of buprenorphine. 
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Table 1-1. Commercially available buprenorphine products.  
 
Trade 
Name 
Dosage 
Form/Route Strength Ingredients Sponsor 
Approval 
Date 
Buprenex 
(US) 
Injection Solution 
/IV or IM 
0.3 mg base/mL buprenorphine HCl (0.324 mg/mL),  
anhydrous dextrose (50 mg/mL), 
water for injection, HCl (adjust pH) 
Reckitt Benkiser 
Pharmaceuticals, 
Inc. 
 
December 29, 
1981 
NA Hospira (generic) June 3, 1996 
NA Bedford (generic) March 2, 2005 
NA Luitpold (generic) March 27, 2007 
Suboxone 
(US) 
Tablet/Sublingual 2mg/0.5mg, 
8mg/2mg 
(buprenorphine 
HCl / Naloxone 
HCl) 
buprenorphine HCl, Naloxone HCl, 
lactose, mannitol, cornstarch, 
povidone K30, citric acid, sodium 
citrate, FD&C Yellow No.6 color, 
magnesium stearate, Acesulfame K 
sweetener and a lemon lime flavor. 
Reckitt Benkiser 
Pharmaceuticals, 
Inc. 
October 8, 
2002 
Suboxone 
(US) 
Film/Sublingual 2 mg/0.5 mg, 
8 mg/2 mg 
(buprenorphine / 
Naloxone) 
buprenorphine HCl, naloxone HCl 
dihydrate, polyethylene oxide, 
hydroxypropyl methylcellulose, 
maltitol, acesulfame potassium, lime 
flavor, citric acid, sodium citrate, 
FD&C yellow #6, and white ink 
Reckitt Benkiser 
Pharmaceuticals, 
Inc. 
August 30, 
2010 
Subutex 
(US) 
 
Tablet/Sublingual 2 mg; 8 mg (base) buprenorphine HCl, lactose, 
mannitol, cornstarch, povidone K30, 
citric acid, sodium citrate and 
magnesium stearate. 
Reckitt Benkiser 
Pharmaceuticals, 
Inc.  
October 8, 
2002  
NA Roxane 
Laboratories , Inc. 
(generic) 
October 8, 
2009 
NA Barr Laboratories, 
Inc. (generic) 
May 7, 2010 
NA EthyPharm 
(generic) 
September 24, 
2010 
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Table 1-1. (Continued). 
 
Trade 
Name 
Dosage 
Form/Route Strength Ingredients Sponsor 
Approval 
Date 
Transtec 
(US) 
ER patch (4-day) 
/Transdermal  
35, 52.5 and 70  
mcg/hr 
NA Grunenthal 2001 
Butrans 
(US) 
ER patch (7-day) 
/Transdermal  
5, 10 and 20 mcg/hr NA Purdue Pharma, 
LLC 
June 30, 2010 
Norspan 
(Australia ) 
ER patch (7-day) 
/Transdermal  
5, 10 and 20 mcg/hr buprenorphine base, levulinic acid, 
oleyl oleate, povidone, Duro Tak 
387-2051, Duro Tak 387-2054 and 
polyethylene terephthalate 
Mundipharma 
and Grunenthal 
April 4, 2005 
Probuphine Implant (6-month) 
/subcutaneous 
NA NA Titan 
Pharmaceuticals, 
Inc. 
July 2008 
(opioid 
addiction, phase 
III; chronic pain, 
phase I) 
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The transdermal buprenorphine patch, Transtec, was first launched in 
Switzerland and Germany in 2001 and is now marketed all over Europe.4 It is used to 
treat moderate to severe cancer pain and severe pain which does not respond to non-
opioid analgesics. It is not suitable for the treatment of acute pain. Butrans is a 7-day 
patch for the relief of moderate to severe pain in patients requiring continuous, around-
the-clock opioid treatment for an extended period of time. It was approved by US FDA 
on June 30, 2010 and marked by Purdue Pharma with the strengths of 5, 10 and 
20 mcg/hr. Norspan is also a 7-day analgesic patch but available in Austrilia.5 It is 
indicated for the treatment of moderate chronic pain not responding to non-opioids, dosed 
in 5, 10 or 20 mcg/hr patches. 
 
Probuphine6 is a novel subcutaneous implant to deliver six months of 
buprenorphine. Titan Pharmaceuticals announced positive, statistically significant results 
from its randomized, double-blind, placebo controlled, multi-center Phase III clinical trial 
of Probuphine for the potential treatment of opioid addiction in July 2008. The phase I 
study of Probuphine on treatment of chronic pain is still going on. 
 
 
1.1.3. Pharmacology of buprenorphine 
 
Buprenorphine is usually described as a “-receptor partial agonist”, “mixed 
opioid receptor agonist-antagonist”, “high affinity mu agonist/kappa antagonist”, or 
“narcotic antagonist analgesic”.7 It is used clinically for pain management and the 
treatment of opioid dependency. The exact mechanisms of action of buprenorphine are 
not fully understood. Antinociceptive effect of buprenorphine is primarily mediated by 
the μ-opioid receptor. The data shows that buprenorphine can attenuate or abolish the 
action of other full agonists, such as morphine, and produce a submaximal 
antinociceptive effect.8-10 Therefore buprenorphine is usually accepted as a “partial” μ-
opioid receptor agonist.11-15 It is also a κ-receptor antagonist.10,16 In addition, recent 
discovery shows that buprenorphine has the affinity to delta and ORL-1 receptor17 (Table 
1-2).  
 
Buprenorphine has a unique bell-shaped dose-response curve for 
antinociception.2,18-20 The analgesia response of buprenorphine in rat tails warm water 
study did not grow with increased dose. The dose for the highest response was found at 3 
mg/kg.20 On the contrary, dose-response curve decreased with increasing dose at high 
dose range. The exact mechanisms are not fully understood. The possible mechanisms 
could be partial agonism at the  opioid receptor and, in some cases, antagonism at the 
kappa or delta opioid receptor.17 Recent data17 suggest that the action of buprenorphine at 
the ORL-1 receptor could be responsible for the ceiling effect and for the bell-shaped 
dose-response curves observed after administration of the drug in the radiant heat tail 
flick assay. The antinociceptive effect of buprenorphine is attenuated by the ability of the 
drug to activate the ORL-1 receptor in opioid receptor knockout mice. 
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Table 1-2. Apparent Ki values of buprenorphine for the various members of the 
opioid receptor family.  
 
Animals Mu Kappa Delta ORL-1 
Rat Brain21 0.08 ± 0.02 0.11 ± 0.05 0.42 ± 0.04 285 ± 30 
Monkey Brain22 0.08 ± 0.01 0.44 ± 0.08 0.82 ± 0.11 not determined 
 
Data are presented as mean ± SEM (nM). 
Source: Lutfy K, Cowan A 2004. Buprenorphine: A unique drug with complex 
pharmacology. Curr Neuropharmacol  2(4):395-402. Reprinted with permission. 
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1.1.4. Pharmacokinetics of buprenorphine 
 
 
1.1.4.1. Pharmacokinetic parameters 
 
Ohtani et al.2,23 published the pharmacokinetic parameters of buprenorphine in 
rats by intravenous administration at doses of 0.06 mg/kg and 0.6 mg/kg, and claimed 
that the plasma concentration of buprenorphine declined biexponentially after 
intravenous administration and the mean t1/2 (elimination half-life), CL (clearance), Vss 
(volume distribution at steady-state), and MRT (mean residence time) values for 
buprenorphine were 2.8 hr, 1.4 L/hr/kg, 4.2 L/kg, and 3.0 hr at the dose of 0.6 mg/kg and  
2.4 hr, 1.32 L/hr/kg, 3.5 L/kg, and 2.8 hr at the dose of 0.06 mg/kg, respectively. Gopal et 
al.24 reported the pharmacokinetic parameters of buprenorphine in rats after receiving a 
single intravenous bolus dose of 0.1, 0.3, 1, 3, 10 or 30 mg/kg. The mean t1/2, CL, Vss, 
and MRT values for buprenorphine were 4.75-5.28 hr, 2.7-6.1 L/hr/kg, 8.37-18.2 L/kg, 
and 3.02-3.83 hr, respectively. Yu et al.25 indicated that the pharmacokinetic values of t1/2, 
CL, and Vss were 2.9 hr, 4.3 L/hr/kg, 6.5 L/kg, respectively, after intravenous 
administration of the buprenorphine solution at the dose of 2.4 mg/kg in the mouse. 
 
 
1.1.4.2. Absorption distribution metabolism and excretion (ADME)  
 
Due to the extensive first-pass effect, the bioavailability of buprenorphine in 
humans following oral administration is approximately 10%.26 The systemic 
bioavailability of buprenorphine varies by various routes of administration in rats. After 
single doses of 0.2 mg/kg buprenorphine solution, the systemic bioavailability of 
buprenorphine has been studied in female rats. The mean bioavailabilities were 
intravenous, 98%; intrarectal, 54%; intrahepatoportal, 49%; sublingual, 13%; and 
intraduodenal, 9.7%, relative to the 100% bioavailability from the intra arterial route.27 
 
After an intravenous dose of 0.2 mg/kg28,29 buprenorphine in the rats, high levels 
of buprenorphine were found in the lung, heart, kidney and liver, and buprenorphine level 
in the brain was higher than that in the plasma. Two metabolic pathways,2 N-dealkylation 
by CYP3A4 and glucuronidation, were well documented in rat, rabbit, dog, baboon, and 
rhesus monkey,15 and could lead to the three major metabolites of buprenorphine, 
buprenorphine-3-glucuronide; N-dealkylbupurenorphine (norbuprenorphine) and 
norbuprenorphine-3-glucuronide. The primary metabolite is buprenorphine-glucuronide 
and the rest are norbuprenorphine and norbuprenorphine-glucuronide. The conjugated 
metabolites, buprenorphine-glucuronide and norbuprenorphine-glucuronide, are mostly 
excreted in bile in rats.23 Independent of species, buprenorphine is mainly excreted 
through the bile23,30 and eliminated in the faeces, and a small amount of metabolites are 
excreted through the urine by urinary excretion.2 Enterohepatic circulation of 
buprenorphine was found in rats, dogs, monkeys and human.23,30,31 The conjugated 
metabolites, buprenorphine-glucuronide and norbuprenorphine-glucuronide, in the bile 
could be absorbed after the return of the parent drugs, buprenorphine and 
norbuprenorphine, to the intestinal tract.2 
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1.2. Injectable Analgesics for Rodents 
 
Current injectable analgesic for rodents can be divided into two groups: opioid 
and non-steroidal anti-inflammatory drug (NSAID) analgesics. The dose, administration 
route and formulation of analgesics for rodents are listed in Table 1-3. 
 
 
1.2.1. Opioid injectable analgesics for rodents 
 
Opioid analgesics are the derivatives of opiates and usually used in moderate to 
severe types of pain for rodents.32 These types of analgesics used in rodents can be 
classified as agonists, partial agonists, and agonist/antagonist. 33 Agents, such as 
morphine, codeine, and propoxyphene, are agonists which bind to central nervous system 
opiate μ-receptors to produce analgesia and reduce the perception of pain. Agents, such 
as buprenorphine, are partial agonists of μ-receptor, but the maximal analgesia produced 
is less than full agonist. Agents, such as butorphanol and nalbuphine, are agonist-
antagonists. These drugs are agonist of some opioid receptors, but act as antagonist at 
other opioid receptors.  
 
 
1.2.1.1. Buprenorphine 
 
Buprenorphine is currently considered as the standard opioid analgesic for rats 
and mice.34 It is the most commonly used and reported35 analgesic for rodents. It is the 
partial agonist for the μ-receptor and has a relatively long duration of analgesic action (8 
to 12 hours). Buprenorphine is used as an analgesic for pain relief after surgical 
procedures and is considered to be approximately 30 times stronger than morphine. 
Buprenorphine is well absorbed after intramuscular (IM) and subcutaneous (SC) 
injection, and is metabolized in the liver. In rats, the drug concentrates in the liver, brain, 
gastrointestinal tract and placenta. It is then excreted in urine, and via breast milk. It is 
therefore not recommended to be given to pregnant or lactating rats.36 
 
The commercial product of buprenorphine is Buprenex. Each mL of Buprenex 
contains 0.324 mg buprenorphine hydrochloride (equivalent to 0.3 mg buprenorphine), 
50 mg anhydrous dextrose, water for injection and HCI to adjust pH. 
 
 
1.2.1.2. Morphine 
 
Morphine is a highly potent opiate analgesic drug which interacts predominantly 
with the μ-opioid receptor. In clinical practice, morphine is regarded as the gold standard 
of analgesics used to relieve severe or agonizing pain. The primary side effect of 
morphine for rodents is respiratory depression. Fortunately, the effects are species 
specific. For example, morphine can produce analgesia without respiratory depression in 
the hamster.44  
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Table 1-3. Recommended analgesics for rats and mice. 
 
Drug Species Dose Administration Route Frequency Formulation of Commercial Product 
Rats 0.01-0.1 mg/kg 37-39 SC37-39, IV37,38 q 6-12 hr37-39 Buprenorphine 
Mice 0.05-0.1 mg/kg 37,39,40 SC37,39,40, IV37 q 12 hr37,40 
q 3-6 hr39 
Buprenorphine hydrochloride (0.324 mg/mL, equivalent to 0.3 
mg buprenorphine per mL);  
Anhydrous dextrose (50 mg/mL);  
Water;   
HCl (adjust pH). 
Rats 2 mg/kg 38,39 SC38,39 q 4-6 hr38,39 Butorphanol 
Mice 1-5 mg/kg39,40 SC39,40 q 6 hr40 
q 8-12 hr39 
Butorphanol tartrate (1 or 2 mg/mL);  
Citric acid (3.3 mg/mL);  
Sodium citrate (6.4 mg/mL); 
NaCl (6.4 mg/mL);  
Benzethonium chloride (0.1 mg/mL, in multiple dose vial only). 
Rats 5 mg/kg37 SC37, 41 sid37 Ketoprofen 
Mice 5 mg/kg37 SC37 sid37 
Ketoprofen (100 mg/mL);   L-arginine (72 mg);  
Benzyl alcohol (1%);   Citric acid (adjust pH). 
Rats 2.5-5 mg/kg39 
10 mg/kg42 
SC39,42, IM42 q 2-4 hr39,42 Morphine 
Mice 2.5 mg/kg 39 
10 mg/kg42 
SC39,42, IM42 q 2-4 hr39,42 
Morphine sulfate pentahydrate (0.5 or 1 mg/mL);  
NaCl (9 mg/mL);  
NaOH and/or HCl (adjust pH). 
Rats 2.5-5 mg/kg37,39 SC37,39, IM37 sid37, bid39 Carprofen 
Mice 1-5 mg/kg37 SC37 sid37 
Carprofen (50.0 mg/mL);  
Arginine (30.0 mg/mL);  
Glycocholic acid (88.5 mg/mL); 
Benzyl alcohol (10.0 mg/mL); 
Lecithin (169.0 mg/mL);  
NaOH (6.17 mg/mL);   
NaOH and/or HCl (adjust pH); 
Water. 
Rats 1-2 mg/kg39,43 SC39,43 sid39,43 Meloxicam 
Mice 1 mg/kg39 SC39 sid39 
Meloxicam (5.0 mg/mL);  
Alcohol (15%);  
Glycofurol (10%);  
Poloxamer 188 (5%);  
NaCl (0.6%);  
Glycine (0.5%);  
Meglumine (0.3%);  
Water; 
NaOH and HCl (adjust pH) 
 
Q: every. 
Sid: once daily. 
Bid: twice daily. 
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Each mL of commercial available morphine sulfate injection contains morphine 
sulfate pentahydrate 0.5 mg or 1 mg and sodium chloride 9 mg. It may also contain 
sodium hydroxide and/or hydrochloric acid for pH adjustment.45 
 
 
1.2.1.3. Butorphanol  
 
Butorphanol is a synthetic opiate agonist-antagonist that is structurally related to 
morphine. Butorphanol binds to opiate receptors at sites in the central nervous system and 
alters perception and response to pain.46 It is more potent than morphine, but unlike 
morphine it possesses less cardiovascular effects, and respiratory center sensitivity. 
 
Butorphanol Tartrate (Torbutrol, Torbugesic, Stadol) is available as Torbutrol 
injectable (0.5 mg/mL in 10 mL vials), Torbugesic injectable (10 mg/mL in 50 mL vials) 
and Stadol injectable (1 mg/mL and 2 mg/mL). Stadol Injection is a sterile, parenteral, 
aqueous solution of butorphanol tartrate for intravenous or intramuscular administration. 
In addition to 1 or 2 mg of butorphanol tartrate, each mL of solution contains 3.3 mg of 
citric acid, 6.4 mg sodium citrate, and 6.4 mg sodium chloride, and 0.1 mg benzethonium 
chloride (in multiple dose vial only) as a preservative. 
 
 
1.2.2. NSAID injectable analgesics for rodents 
 
Non-steroidal anti-inflammatory drugs (NSAIDs) can be classified as traditional 
cyclooxygenases (COX) inhibitor and COX-2 inhibitor. Traditional NSAIDs have been 
used more for mild pain and anti-inflammation activities than for chronic pain.47 While 
2nd generation NSAIDs can alleviate acute pain, such as that produced by surgery48 and 
have significant analgesic properties which overlap with the activity of the opioids.47 
 
First generation of NSAIDs, such as Aspirin, can decrease the production of 
prostaglandin by inhibiting COX, which reduces pain and also inflammation. Research 
suggested that most of the adverse effects of NSAIDs were regulated by blocking the 
COX-1 enzyme, while the analgesic effects were mediated by the COX-2 enzyme. Thus 
the 2nd generation COX2 inhibitors, such as carprofen and meloxicam, were developed to 
inhibit only the COX-2 enzyme. 
  
NSAIDs can be administered via IM, SC or PO. The metabolism and excretion of 
NSAIDs vary widely among agents and species. In general, the NSAIDS are metabolized 
by the liver and excreted by the kidneys.47 
 
 
1.2.2.1. Carprofen 
 
Carprofen also belongs to NSAID which is a selective COX-2 inhibitor. It is used 
in the treatment of pain for either short term or long term use. It can also be used as an 
alternative to opioid based post-operative pain. Usually carprofen is used to treat post-
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operative, injury-related, and chronic (e.g., cancer-related) pain in dogs and cats as well 
as rabbits, coatis and many small mammals.49 Carprofen for animals is one of the most 
reliable and useful active principles available to veterinarians for treating animals in pain. 
It has a dual mode of action: -receptor agonism and mono-amine reuptake inhibition, 
which produces mild anti-anxiety results.50 The advantage of this drug is less respiratory 
and cardiovascular side effects than the opioids, and longer acting time. Recommended 
dose of carprofen for rats is 5-10 mg/kg orally51 or 5-10 mg/kg SC.52 
 
The drug is metabolized in the liver and primarily eliminated in feces with a small 
percentage being eliminated in the urine. There is some enterohepatic recycling of the 
drug.  
 
Carprofen is marketed under 75 trade names49 around the world. Carprofen is 
available as Tramadol hydrochloride injection (50mg/1ml and 100mg/2ml),53 which is 
not currently marketed in the US for human use, but it is still available in other 
countries.54 Each mL of carprofen Injectable contains 50.0 mg carprofen, 30.0 mg 
arginine, 88.5 mg glycocholic acid, 169.0 mg lecithin, 10.0 mg benzyl alcohol, 6.17 mg 
sodium hydroxide, with additional sodium hydroxide and hydrochloric acid as needed to 
adjust pH, and water for injection.55 
 
 
1.2.2.2. Meloxicam 
 
Meloxicam is also a NSAID and shows a more selective inhibition of COX-2. It is 
used to treat mild to moderate to severe pain in rats. Meloxicam is relatively expensive 
and thus may not be practical for everyday use.  A dose of 1-2 mg/kg orally or 
subcutaneously once a day for rats has been given.56 Both injectable and oral 
formulations of meloxicam have been licensed for use in dogs and injectable ones for use 
in cats since 1980’s. 
 
The commercial product of Meloxicam is Metacam. Each mL of this sterile 
product for injection contains meloxicam 5.0 mg, alcohol 15%, glycofurol 10%, 
poloxamer 188 5%, sodium chloride 0.6%, glycine 0.5%, and meglumine 0.3%, in water 
for injection, pH adjusted with sodium hydroxide and hydrochloric acid.57 
 
 
1.2.2.3. Ketoprofen 
 
Ketoprofen is a propionic acid derivative.58 It is a NSAID which inhibits both the 
cyclooxygenase and lypoxygenase pathways of arachidonic acid breakdown. It is a 
potent, non-narcotic analgesic and anti-pyretic agent.59 
 
Ketoprofen is available as Anafen Injection (100 mg/mL). Each mL contains 100 
mg ketoprofen, 72 mg L-arginine, 1% benzyl alcohol as a preservative and suitable citric 
acid to adjust pH.60 
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1.3. Sustained Release Analgesic Formulations in Animals 
 
Several sustained release analgesic formulations have been studied in animals. 
Transdermal fentanyl patches have been studied in cats61, dogs61,62, sheep63,and rabbits64 
for up to 72 hours. Liposomal formulations of opioid analgesics have been tested in mice 
and rats. Administration of liposomal oxymorphone at the time of surgery improved 
postsurgical recovery in mice.34 Liposome-encapsulated oxymorphone was found to 
provide prolonged relief of postsurgical visceral pain for at least 48 hr in a rat short-gut 
syndrome model.65  Liposome-encapsulated oxymorphone or morphine was effective in 
preventing hyperalgesia in rat neuropathic pain model for up to seven days.66 Liposome-
encapsulated opioid analgesic, hydromorphone, was tested in a chronic constriction 
injury thermal hyperalgesia rat model of neuropathic pain, and found that preemptive 
injection of liposome-encapsulated hydromorphone prevented hyperalgesia in this model 
for five days.67 However, these tested sustained release analgesic patches or liposomal 
formulations were not practical and economic to rodents. In 2011, commercially 
available buprenorphine HCl sustained release product was announced by ZooPharm 
(Fort Collins, CO). The formulation is composed of a biocompatible organic solvent and 
biodegradable copolymer with an average molecular weight of approximately 5500 Da 
and a 50:50 molar ratio of DL-lactide to ε-caprolactone. It was claimed that the 
formulation could provide sustained release of buprenorphine for 72 hours after 
subcutaneous administration.68 The disadvantages of this polymeric delivery system are 
potential irritation and relatively expensive considering the large amount of rodents used 
in research. 
 
 
1.4. In Vitro Dissolution Model for Parenteral Dosage Forms 
 
So far there are no standard regulatory methods for parenteral sustained release 
products at present.69,70 Over the past decade, several methods have been attempted to 
describe drug release from parenteral products and the current in vitro release methods for 
parenterals might be divided into four broad categories (Figure 1-2): sample-and-
separate (SS),69,70 continuous flow (CF),69,70 ultrafiltration,70 and dialysis techniques 
including rotating dialysis,71 dialysis sac,70 and microdialysis.70 The advantages and 
disadvantages of each method were discussed by Diane J. Burgess70 and Claus Larsen.69 
 
Sample-and-separate method69 is a closed system and generally used to test 
microsphere based or gel formulations. The formulation is introduced into a vessel/vial 
containing the release medium. The experiment is then conducted at constant temperature 
with agitation. At predetermined time intervals, samples are taken from the supernatant 
and analyzed for released drug content. After sampling, same volume of fresh medium is 
added to the system to maintain a constant volume. 
 
USP (United States Pharmacopeia) apparatus 4 is the commonly used continuous 
flow method69,72 for microparticulate systems. The microparticulate formulation is 
usually placed in the release cell and the dissolution medium is pumped into the cell at 
constant flow rate. The drug content can be analyzed directly from the effluent and
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Figure 1-2. Schematic illustration of different in vitro dissolution methods for parenterals.  
 
(A) Sample and separation method (S-S).  
(B1) Closed-loop and (B2) open-loop configuration for flow-through cell apparatus.  
(C) Ultrafiltration technique.  
(D1) Dialysis membrane-based technique (DMB).  
(D2) Rotating dialysis cell model.  
(D3) Reversed dialysis sac technique.  
(D4) Microdialysis sampling technique.  
Source: Larsen C, Larsen SW, Jensen H, Yaghmur A, Ostergaard J 2009. Role of in vitro release models in formulation development 
and quality control of parenteral depots. Expert Opin Drug Deliv  6(12):1283-1295. Reprinted with permission. 
Source: Krishna R, Yu L 2008. Biopharmaceutics Applications in Drug Development.336-358. Reprinted with permission. 
Source: Schultz K, Mollgaard B, Frokjaer S, Larsen C 1997. Rotating dialysis cell as in vitro release method for oily parenteral depot 
solutions. Int J Pharm  157(2):163-169. Reprinted with permission. 
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medium can be recirculated into the system, or monitored after collecting the samples.  
 
Ultrafiltration73 is a membrane filtration technique. This separation technique is 
usually used to purify and concentrate macromolecular solutions, especially protein 
solutions. Low molecular weight solutes pass through the semipermeable membrane and 
suspended solids and solutes of high molecular weight are retained. In order to solve the 
difficulty of separation of the delivery system from the media, ultrafiltration70,74 method 
is proposed for the evaluation of drug release profile from colloidal carriers such as 
submicron emulsions and nanoparticles at low pressure. It was claimed that ultrafiltration 
method at low pressure was versatile, sensitive and capable of distinguishing between 
different kinetic behaviors. 
 
The dialysis membrane-based (DMB) method most often can be referred to as 
two-compartment release model. It usually consists of a small donor compartment and a 
large acceptor compartment separated by the dialysis membrane. Among the DMB 
methods, (1) rotating dialysis cell model71 is well characterized and consists of a small 
donor compartment (5-8 mL) and a large acceptor compartment (1000 mL) separated by 
a dialysis membrane. Lipophilic (oily) solutions, aqueous suspensions, microspheres and 
liposomes have been tested in this model and the drug release mechanism has been well 
characterized. Also the in vitro and in vivo correlation has been established for a 
particular formulation in this model. (2) Float A Lyzer69 is the commercially available 
dialysis membrane-based model which works with the gentle agitation in the donor 
compartment, resulting in lower drug transport rates. (3) In dialysis sac70,75 system, 
dispersed phase (e.g. emulsion) is directly placed into the large donor chamber with the 
stirred sink solution and the sacs contain only media. At predetermined time intervals, 
dialysis bags were withdrawn for drug content analysis. (4) Microdialysis technique76 
usually is used for continuous measurement of free, unbound analyte concentrations in 
the extracellular fluid of virtually any tissue. The microdialysis probe consists of a shaft 
with a semipermeable hollow fiber membrane at its tip, which is connected to inlet and 
outlet tubing. The microdialysis system used for parenterals70,75 consists of the syringe 
pump, microdialysis probe, 40-mesh screen and a magnetic stirrer system. The implant 
was usually placed on the screen, and the microdialysis probe was placed at a fixed 
distance from the implant. The release medium was constantly stirred with the aid of a 
magnetic stirrer at the bottom of the reservoir. At predetermined time intervals, the 
samples were collected directly into the autosampler injection vials and drug content was 
further determined.  
 
 
1.5. IVIVC 
 
 
1.5.1. Definition  
 
An  in vitro-in vivo correlation (IVIVC) has been defined by the Food and Drug 
Administration (FDA) as "a predictive mathematical model describing the relationship 
between an in vitro property (usually the extent or rate of drug release) and a relevant in 
 17 
vivo response (e.g. plasma concentration or amount of drug absorbed)".77  The United 
States Pharmacopoeia (USP) also defines IVIVC as "the establishment of a relationship 
between a biological property, or a parameter derived from a biological property 
produced by a dosage form, and a physico-chemical characteristic of the same dosage 
form".78 
 
 
1.5.2. Categories  
 
According to the FDA, IVIVC are categorized as Levels A, B, C and Multiple C. 
The classification of correlation level is based upon the ability of predictive mathematical 
model to correlate the entire plasma drug concentration time curve or other important 
pharmacokinetic parameters with the in vitro dissolution profile or parameters. According 
to FDA guidance, (1) Level A correlation is “a predictive mathematical model for the 
relationship between the entire in vitro dissolution/release time course and the entire in 
vivo response time course (e.g., the time course of plasma drug concentration or amount 
of drug absorbed)”.78 Level A correlation is general linear and represents a point-to-point 
relationship between in vitro dissolution and the in vivo input rate of the drug from the 
dosage form. The key of the correlation is point-to-point correlation and therefore the in 
vitro dissolution and in vivo input rate curves can share the same mathematical equation 
to describe the drug release behavior. (2) Level B correlation is “a predictive 
mathematical model for the relationship between summary parameters that characterize 
the in vitro and in vivo time courses (e.g., models that relate the mean in vitro dissolution 
time to the mean in vivo dissolution time, the mean in vitro dissolution time to the mean 
residence time in vivo, or the in vitro dissolution rate constant to the absorption rate 
constant)”.78 A Level B correlation utilizes all of the in vitro and in vivo data, but it is not 
considered to be a point-to-point correlation since it does not reflect the entire in vivo 
plasma level curve. Since Level B correlation cannot uniquely reflect the actual in vivo 
plasma level curve, it has less application than Level A correlation. It is least useful for 
regulatory purposes. (3) Level C correlation is “a predictive mathematical model of the 
relationship between the amount dissolved in vitro at a particular time (or the time 
required for in vitro dissolution of a fixed percent of the dose, e.g., T50%) and a 
summary parameter that characterizes the in vivo time course”.78 Level C represents a 
single point correlation between one dissolution time point (e.g., T50%, T90%) and one 
important pharmacokinetic parameter (e.g., AUC, Cmax or Tmax). Level C correlations can 
be useful in the early stages of formulation development when pilot formulations are 
being selected. (4) A multiple Level C correlation represents relationship between the 
amount of drug dissolved at several time points of the dissolution profile and one or 
several pharmacokinetic parameters of interest. Multiple Level C correlations can be as 
useful as Level A correlations. But if a multiple Level C correlation is possible, then a 
Level A correlation is also likely and is preferred.78 
 
Level A correlation is the most informative and useful for waiver of an in vivo 
bioequivalence study (biowaiver). Level B and C IVIVCs have been applied in 
formulation development, optimizing manufacturing processes, quality control processes, 
and characterizing the release patterns of newly formulated IR and modified-release 
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products relative to the references.79  A multiple Level C correlation may be used to 
justify a biowaiver by establishment of the correlation over the entire dissolution profile 
with one or more pharmacokinetic parameters of interest. 
 
 
1.5.3. Evaluation  
 
The objective of developing IVIVC is to establish a predictive mathematical 
model describing the relationship between an in vitro property and a relevant in vivo 
response.78 It is recommended by FDA that the IVIVC relationship should be 
demonstrated consistently with two or more formulations with different release rates to 
result in corresponding differences in absorption profiles. The evaluation of IVIVC 
should be able to demonstrate that predictability of in vivo performance of a drug product 
from its in vitro dissolution profile. Generally, Level A IVIVC validation can be assessed 
by prediction of plasma profiles or AUC from in vitro dissolution data using the 
developed IVIVC.  
 
The objective of IVIVC evaluation is “to estimate the magnitude of the error in 
predicting the in vivo bioavailability results from in vitro dissolution data”.78 Two criteria, 
internal and external criteria, are required for the validation process. (1) Internal 
predictability is based on the initial data used to define the IVIVC model and should be 
studied for all IVIVCs. The criteria of internal predictability are that “average absolute 
percent prediction error (% PE) of 10% or less for Cmax and AUC establishes the 
predictability of the IVIVC. In addition, the %PE for each formulation should not exceed 
15%”. Percent prediction error (% PE) is calculated by Equation 1-1. (2) Evaluation of  
 
100 Pr % 
valueObserved
valueedictedvalueObservedPE  (Eq. 1-1)
 
 
external predictability of the IVIVC should be performed as a final determination of 
established IVIVC to be used as a surrogate for bioequivalence if the internal 
predictability of the IVIVC is inconclusive.78 This evaluation is based on additional test 
data set that was not used in developing the IVIVC model, and the important criterion is 
that “% PE of 10% or less for Cmax and AUC establishes the external predictability of an 
IVIVC”. 
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CHAPTER 2.    DEVELOPMENT OF A SUSTAINED RELEASE 
BUPRENORPHINE FORMULATION FOR MAINTAINING PROLONGED 
ANALGESIA IN RATS AND MICE 
 
 
2.1. Introduction 
 
Rodents are the most universally used laboratory animals and are often subjected 
to research involving painful procedures. In US, the National Association for Biomedical 
Research (NABR) estimated that 23 million rats and mice were needed for research in 
1998 and that rodents accounted for 95% of the animals used.80 The Home Office showed 
that 3.6 million animals were used in scientific procedures in 2010 and 80% of them were 
rats and mice in the UK.81 Animal welfare regulations require that anesthetic or analgesia 
should be provided to the animals involved in painful procedures.  
 
Numerous studies cite buprenorphine as a potent opioid analgesic for managing 
pain in rodents as it exhibits excellent analgesic activity and minimal side effects.12,82-87 A 
survey of current literature indicates that buprenorphine is one of the most widely used 
analgesics in rodents for its excellent analgesic activity and long duration of action 68,88-90 
and has been extensively used in both laboratory and companion animals for almost three 
decades.90 Buprenorphine has a complex pharmacological profile. It is generally accepted 
that buprenorphine is μ-opioid receptor partial agonist, κ-opioid receptor antagonist, and 
δ-receptor agonist.87 It has a broad analgesic profile, relative wide safety margin91 and 
offers the opportunity to treat different pain conditions for rodents.92 Elizabeth A. Tolley 
et al demonstrated that buprenorphine has a analgesia duration of 6 to 8 hr in rats (0.5 
mg/kg) and 3 to 5 hr in mice (2.0 mg/kg) after subcutaneous injection buprenorphine 
solution using conventional hot-plate and tail-flick assays.93 But in order to maintain 
effective analgesia levels, buprenorphine must be administered at least 2 or 3 times daily 
for each animal. Frequent dosing requires more personnel effort and more handling to the 
animals. However, no commercial sustained release analgesic for rodents was available 
when we started the project in 2008. In 2011, Patricia L Foley68 published a 
biodegradable polymer delivery system composited of buprenorphine hydrochloride, a 
biocompatible organic solvent, and DL-lactide-ε-caprolactone copolymer with an average 
molecular weight of approximately 5500 Da. It was claimed that this product could 
provide a 48 to 72 hours period of analgesia for rats. But skin irritation is potentially a 
problem for this product.68 The other disadvantage of this product is that the cost of 
biodegradable polymer delivery system is much higher than the hydrophobic based 
solution system.  
 
Parenteral long-acting lipophilic solutions have been in clinical use for more than 
three decades.94 Compared with other parenteral delivery system, the composition is 
relatively simple and has the attributes94 of uncomplicated manufacture and feasible long-
term stability. Some citric acid esters, such as acetyl triethyl citrate (ATEC), acetyl 
tributyl citrate (ATBC), acetyl trihexyl citrate, and acetyl trioctyl citrate, are safe to use in 
cosmetics.95 Both ATEC and ATBC were nonirritating to the skin in rabbits and human 
clinical studies.95 These indicated the potential to apply citric acid esters as nonirritating 
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and low cost vehicles in drug delivery. In order to reduce the stress of frequent handling 
and injection as well as improve the welfare of research animals, this study developed a 
long-acting sustained release hydrophobic formulation of buprenorphine which is capable 
of maintaining analgesia in rats and mice for 3 to 5 days following a single subcutaneous 
administration.  
 
 
2.2. Materials and Methods 
 
 
2.2.1. Materials 
 
Buprenorphine base was obtained from Diosynth Inc. (Morrisville, NC).  Triethyl 
citrate (TEC), acetyl triethyl citrate (ATEC), tributyl citrate (TBC) and acetyltributyl 
citrate (ATBC) were obtained from Vertellus Specialties Inc. (Greensboro, NC). 
Polyethylene glycol 400 (PEG 400) was obtained from Dow Chemicals, Inc. (Danbury, 
CT). Soybean oil and corn oil were obtained from Croda, Inc. (Columbus Circle Edison, 
NJ). Ethyl benzoate and benzyl benzoate were purchased from Sigma Aldrich (Atlanta, 
GA).  
 
 
2.2.2.  Animals 
 
Male Sprague Dawley rats (approximately 300 g) and mice (approximately 30 g) 
were obtained from Charles River Laboratories (Wilmington, MA).  The animals were 
group-housed in polycarbonate caging with ad libitum access to food and water. The 
experiments were conducted according to protocols approved by the Institutional Animal 
Care and Use Committee (IACUC).  
 
 
2.2.3. Analytical methodology for in vitro and in vivo studies 
 
 
2.2.3.1. Analytical methodology for in vitro studies 
 
Two different HPLC methods were developed to quantitate buprenorphine in 
samples obtained from in vitro studies. Method 1 was used for equilibrium solubility and 
dissolution studies. Method 2 was used for stability studies. A silica-gel column was used 
in Method 2 rather than C-18 column in Method 1 was because multiple injections of 
buprenorphine samples containing highly lipophilic excipients resulted in contamination 
of C-18 column and low sensitivity of the assay. 
 
 
2.2.3.1.1. HPLC method 1 for equilibrium solubility and dissolution studies 
The mobile phase used in method 1 was composed of a mixture of 51 mM 
KH2PO4 buffer (pH 5.35) containing 0.0675% (v/v) of 2N NaOH and acetonitrile (45:55, 
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v/v). A discovery C-18 column (2.1 x 100 mm) (Supelco, Bellefonte, PA) was used.  The 
oven temperature was 40°C and the flow rate was 0.3 mL/min. The total run time was 6 
minutes. Buprenorphine was detected with a florescence detector at λExitation = 292 nm and  
λEmission= 350 nm.  
 
 
2.2.3.1.2. HPLC method 2 for stability studies 
 
Waters Silica-gel column (4.6х150 mm) (Milford, MA) was used for this method.  
The mobile flow rate was 1.0 mg/min. A mixture of 50 mM sodium acetate (pH was 
adjusted to 3.75 with acetic acid) and acetonitrile (20:80, v/v) was used as the mobile 
phase. Total run time was 7 minutes. Buprenorphine was detected with florescence 
detector at λExitation = 292 nm and λEmission= 350 nm.  
 
 
2.2.3.1.3. Preparation of standard solutions 
 
The primary standard stock solution (1.68 mg/mL) for the validation study of 
Method 1 was prepared by accurately weighing 16.8 mg of buprenorphine, dissolving it 
with acetonitrile and diluting the resulting solution to 10 mL with acetonitrile. The 
secondary standard working solutions (0.038, 0.076, 0.38, 7.6 and 38 μg/mL) were 
prepared by serially diluting the primary standard stock solution with 50% ACN. To test 
intra-day accuracy, a set of standard samples were injected 3 times on the same day. To 
test inter-day accuracy, three sets of standard samples were freshly prepared individually 
every day and then injected once every day. 
 
The primary standard stock solution (1.17 mg/mL) for the validation study of 
Method 2 was prepared by accurately weighing 11.7 mg of buprenorphine, dissolving it 
with acetonitrile and diluting to 10 mL with additional acetonitrile. The secondary 
standard working solutions (0.03, 0.12, 0.29, 1.17 and 5.85 μg/mL) were prepared by 
serially diluting the primary standard stock solution with 50% ACN. To test intra-day 
accuracy, a set of standard samples were injected 5 times on the same day. To test inter-
day accuracy, three sets of standard samples were freshly prepared individually every day 
and then injected once every day.  
  
 
2.2.3.2. Analytical methodology for in vivo studies 
 
Validated LC/MS/MS methods were developed for quantifying the drug 
concentrations in plasma samples obtained from in vivo studies.  
 
 
2.2.3.2.1. Equipment 
 
The HPLC system consisted of two Shimadzu LC-10ADvp pumps (Shimadzu 
Scientific Instruments Inc., Columbia, MD), a Shimadzu SIL-HTc autosampler, and a 
 22 
HILIC silica column (5 m, 150 × 4.6 mm) with a guard column (10 × 2.1 mm) (Waters 
Inc., Milford, MA). Harvard syringe pump (Harvard Apparatus, South Natick, MA). API 
4000 tandem triple quadrupole mass spectrometer (Applied Biosystems, Foster City, CA) 
and Source SF 5000 LC/MS Gas Generator (Parker Hannifin, Haverhill, MA) were also 
used. Analyst® software (Applied Biosystems, Version 1.4.1, Foster City, CA) was used 
for data acquisition and processing.  
 
 
2.2.3.2.2. HPLC conditions  
 
A gradient method was used to supply eluent to the mass spectrometer.  The 
mobile phase consisted of solutions A and B.  Solution A consisted of ACN : water : 
formic acid (4.95:95:0.05, v/v) containing 2 mM ammonium formate.  Solution B 
consisted of ACN : water : formic acid (95:4.95:0.05, v/v) containing 2 mM ammonium 
formate. The time program of the gradient method was such that it started with 90% of 
Solution B and 10% of Solution A.  The concentration of Solution B was then decreased 
linearly from 90% to 40% within 3.5 minutes and then immediately increased to 90% and 
maintained at 90% for 2 minutes.  The concentration of Solution B was then decreased 
linearly from 90% to 40% within 0.5 minute and then linearly increased to 90% within 
0.5 minute and maintained at 90% for 4 minutes. The total run time was 10 minutes.  The 
column was operated at room temperature and the flow-rate of the mobile phase was 0.5 
mL/min.  
 
 
2.2.3.2.3. Switch valve  
 
The eluent from the HPLC system was only introduced directly into the mass 
spectrometer between running time of 4.6 min and 5.6 min. The eluent from the HPLC 
system within the first 4.6 minutes and after 5.6 minutes was introduced directly into the 
waste collector.   
 
 
2.2.3.2.4. MS conditions 
 
The MS was set in the positive ion mode. The ion-spray voltage was 5.0 kV and 
desolvation temperature was 600ºC.  Ion source gas one, ion source gas two, curtain gas 
and collision gas flows were set at 55, 60, 14, and 6 of the instrument units, respectively.  
The mass analyzer was set at multiple-reaction-monitoring (MRM) mode with a dwell 
time of 300 ms for each ion pair.  Ion transition of 468.3 to 468.3 was selected for 
buprenorphine detection and 472.3 to 472.3 for buprenorphine-D4 detection.  The 
compound dependent parameters for buprenorphine and buprenorphine-D4 were as 
follows: declustering potential (DP) of 47, entrance potential (EP) of 10, collision energy 
(CE) of 50, and collision cell exit potential (CXP) of 13.  Resolution of the mass analyzer 
was set at unit resolution.  Optimization of the mass spectrometric conditions were 
carried out by infusing 50 ng/mL of analyte solution dissolved in a mixture of acetonitrile 
and water (50/50, v/v) at 10 L/min using a syringe pump. 
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2.2.3.2.5. Process of plasma samples 
 
The internal standard solution (50 ng/mL) of buprenorphine-D4 was prepared by 
diluting buprenorphine-D4 standard solution (100 g/mL) with 0.1% formic acid 
solution. Twenty-five microliters of rat plasma was spiked with 25 µL of Buprenorphine-
D4 internal standard solution and 25 L of 50% ACN.  The resulting mixture was mixed 
well by vortexing for 10 seconds and centrifuged at 14K rpm for 1 minute, and then 
deproteinated by adding 25 L of 15% trichloroacetic acid solution.  The mixture was 
then vortexed for one minute and kept in -20ºC for 30 minutes.  The samples were then 
centrifuged for 10 minutes at 14k rpm using an Eppendorf 5415C centrifuge (Brinkman 
Instruments Incorporated, Westbury, NY).  The supernatant was transferred to HPLC 
sample vials and the drug content of the samples was determined by the above mentioned 
validated LC/MS/MS assay. The ratio of peak area of buprenorphine to that of peak area 
of buprenorphine-D4 was used to determine the buprenorphine plasma concentration. 
 
 
2.2.3.2.6. Preparation of calibration standard samples and quality control samples 
 
The primary standard stock solution (500 g/mL) for buprenorphine calibration 
standard samples was prepared by accurately weighing approximately 25 mg of 
buprenorphine and dissolving it in 10 mL volumetric flask with ACN. The secondary 
standard working stock solutions with the following concentrations - 0.4, 2, 10, 50, 100, 
150, 200, and 250 ng/mL were prepared by serially diluting the primary standard stock 
solution with 50% ACN. The calibration standard samples were prepared as follows: 
twenty-five microliters of rat plasma was spiked with 25 µL of Buprenorphine-D4 
internal standard solution and 25 L of secondary standard working stock solutions.  The 
resulting mixture was mixed well by vortexing for 10 seconds and centrifuged at 14K 
rpm for one minute, and then deproteinated by adding 25 L of 15% trichloroacetic acid 
solution.  The mixture was then vortexed for one minute and kept at  
-20ºC for 30 minutes.  The samples were then centrifuged for 10 minutes at 14k rpm 
using a centrifuge.  The supernatant was transferred to HPLC sample vials and the drug 
content of the samples was determined by a validated LC/MS/MS assay.    
 
Four standard samples (2, 50, 100, 200 ng/mL) were injected three times in the 
same day to test the intra-day accuracy assay. Two more sets of the standard samples (2, 
50, 100, 200 ng/mL) were freshly prepared in different day and analyzed to test the inter-
day variation. The primary quality control (QC) stock solution (500 μg/mL) was 
independently prepared by weighing approximately 25 mg of buprenorphine powder and 
dissolving it with ACN. The QC working solutions (2, 50, 100, and 200 ng/mL) were 
prepared by serially diluting the primary QC stock solution with 50% ACN solution.  
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2.2.4. In vitro studies 
 
 
2.2.4.1. Determination of equilibrium solubility of buprenorphine 
 
Buprenorphine base powder (approximately 300 mg) was suspended in 1.0 mL of 
solvents (TEC, ATEC, TBC, ATBC, Ethyl benzoate, benzyl benzoate, PEG 400, soybean 
oil and corn oil) in 2.0 mL Eppendorf centrifuge tubes.  After vortexing, the resulting 
suspensions were then shaken at 100 rpm in a shaking incubator maintained at 25ºC and 
37ºC. After 1, 2 and 5 days, the suspensions were vortexed again and then centrifuged at 
12K rpm for 5 minutes. Approximately 100 µL of the clear supernatant was carefully 
removed and the buprenorphine samples were diluted with acetonitrile. One milliliter of 
this solution was further diluted with acetonitrile-water mixture (50:50, v/v) and analyzed 
using a validated HPLC method.  
 
 
2.2.4.2. Determination of stability of buprenorphine in various solvents  
 
Approximately 200 µL of saturated or nearly saturated buprenorphine solutions in 
different solvents (TEC, ATEC, TBC, ATBC, Ethyl benzoate, benzyl benzoate, PEG 400, 
soybean oil and corn oil) were diluted to 10 mL by adding the respective solvents. After 
filtration, the resulting solutions were stored at 25ºC and 40ºC. At 0, 7, 14, 21 and 28 day, 
100 µL of the solutions were removed from the containers and diluted to 10 mL in 
volumetric flasks with acetonitrile. The resulting diluted solution was then analyzed for 
drug content using a validated HPLC method. 
 
 
2.2.4.3. In vitro drug release study 
 
Six solvents were selected for in vitro formulation screening test based on the 
results of aforementioned studies. An appropriate amount of buprenorphine base powder 
was accurately weighed and added to an appropriate amount of solvent in 20 mL glass 
scintillation vials.  The subsequent suspension was sonicated in a water bath maintained 
less than 25ºC until all drug powder was dissolved. The drug content was verified by 
HPLC method. The formulation composition was listed in Table 2-1 and the 
buprenorphine concentration is 1.5% (w/w). 
 
Approximately 210 mg of buprenorphine solution was weighed and carefully 
transferred into the cavity of a Teflon cylinder (internal diameter of the cavity was 15.0 
mm, internal depth was 4.1 mm, height of the cylinder was 12.3 mm, and the outside 
diameter of the cylinder was 20 mm).  The solution-loaded Teflon was then covered with 
a 40-mesh USP basket and centered at the bottom of 1L dissolution vessel. 
Approximately 900 mL of 10% isopropyl alcohol (IPA)-40% water-49.95% phosphate 
buffer saline solution (PBS) (v/v/v) dissolution medium (pH 7.4) containing 0.05% SDS 
was carefully transferred into each vessel at the rate of 7 mL/sec using modified Hanson  
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Table 2-1. Buprenorphine sustained release formulations for in vitro dissolution 
studies. 
 
Formulation Solvent Concentration of Buprenorphine in Solvent (w/w) 
1 TEC 1.5% 
2 ATEC 1.5% 
3 TBC 1.5% 
4 ATBC 1.5% 
5 Benzyl Benzoate 1.5% 
6 Ethyl Benzoate 1.5% 
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Media Mate (Hanson Research Corp.). The ion strength calculated by Debye–Hückel 
equation was adjusted by sodium chloride and kept at 0.13. The new designed apparatus 
was used and the paddle speed was set at 100 rpm. The details of the apparatus will be 
discussed in Section 3.3.6.1. The vessels were covered with a lid and tightened with 
laboratory para-film in order to avoid evaporation of the medium.  
 
The in vitro drug release studies were conducted in triplicate. At 0, 30 min, and 1, 
2, 4, 6, 9, 12, 24, 36, 48, 60, 72, 84, 96 and 120 hours. Approximately 1 mL dissolution 
medium was carefully withdrawn by Hanson Autosampler (Hanson Research Corp.) and 
replaced with 1 mL pre-warmed fresh dissolution medium. The dissolution samples were 
filtered through 0.45 µm PVDF membranes and analyzed for drug content using the 
validated HPLC Method.  
 
 
2.2.5.  In vivo studies 
 
 
2.2.5.1. Measurement of analgesia in rats and mice using the tail flick method  
 
The tail flick method is classic method to evaluate the pain of analgesic. The tail-
flick test apparatus (Model 33, IITC Life Science, Woodland Hills, CA) was used to 
measure analgesia in animals following the administration of the buprenorphine 
solutions. In the tail flick test, the animal tail was exposed to a hot-light beam. When the 
pain threshold was reached, the animal flicked the tail away from the heat beam. The 
time is recorded and the analgesic effect at each time point was reported as the 
Percentage of Maximum Possible Effect (% MPE). This method compares the latency at 
each time point with the animal’s own average baseline latency. %MPE was calculated 
using Equation 2-1.  
 
 100%LatencyBaselineTimeCutoff
LatencyBaselineLatency%MPE 
  (Eq. 2-1)
 
 
where latency is the response time for the animal to flick the tail away from the hot light 
beam; the cutoff time was set at 10 seconds to prevent any possible tissue damage; and 
the baseline latency for each animal was obtained 24 hours prior to the administration of 
the formulations and reported as the average value of three measurements. The intensity 
of light beam was set at the conditions under which the baseline latency of a normal 
untreated rat was approximately 3 to 4 seconds. 
 
 
2.2.5.2. PK and PD studies of buprenorphine in rats after an intravenous injection of 
buprenorphine solution  
 
Six male Sprague Dawley rats with implanted vascular access ports (VAP) were 
used in this study. Before blood samples were withdrawn, the pharmacodynamic activity 
was evaluated via aforementioned tail flick method. Rats were then anesthetized lightly 
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with isoflurane, and 0.05 mg/kg of aqueous solution of buprenorphine hydrochloride was 
injected intravenously via saphenous vein over 10 sec. Blood samples (0.2 mL) were 
withdrawn through the VAP at 0, 5, 15, and 30 min, and 1, 2, 3, 6, 12 and 24 hr after 
administration, and collected in heparinized vial. Plasma was separated from whole blood 
by centrifuging the blood samples at 14k rpm for 7 min and stored at -20ºC until analyzed 
for drug content. Plasma samples were processed and then analyzed using the validated 
LC/MS/MS method.  
 
 
2.2.5.3. PK and PD studies of buprenorphine in rats after a subcutaneous injection of 
buprenorphine sustained release formulations  
 
An appropriate amount of buprenorphine base powder was accurately weighed 
and added to an appropriate amount of TBC in 20 mL glass scintillation vial (Tables 2-2 
and 2-3).  The subsequent suspension was sonicated periodically in a water-bath 
maintained less than 25°C until all drug powder was dissolved. The final solution was 
obtained by filtering the above solution through a 0.22 μm syringe filter into 20 mL 
presterilized glass vial in a sterile hood and the drug concentration was verified by HPLC 
method. 
 
Table 2-2 lists all the investigated buprenorphine formulations in rat studies. The 
tested solvents were selected based on the results of the solubility and stability studies. 
During the animal experiment, buprenorphine solutions (~ 0.2 mL) were administered 
subcutaneously into rats. The syringes were weighed before and after subcutaneous 
administration of the solutions, and the exact weight of the buprenorphine solution 
administered to each rat was noted. 
 
Before blood samples were withdrawn, the pharmacodynamic activity was 
evaluated via aforementioned tail flick method. Blood samples (~ 0.2 mL) were then 
withdrawn from the saphenous vein at predetermined time points and kept in heparinized 
Microvette tubings (Microvette CB 300 LH, Sarstedt, Nümbrecht, Germany). The 
collected blood samples were immediately centrifuged at 14K rpm for 7 min and plasma 
samples were stored at -20°C until further analysis. The plasma samples were processed 
and analyzed for drug content using the validated LC/MS/MS method. The plasma 
concentration at each time point was reported as average ± SD (standard deviation). At 
120 hours (day 5) after subcutaneous administration of the buprenorphine solutions, the 
rats were anesthetized by overdosing with isoflurane, followed by pneumothorax 
euthanasia. The injection sites on the carcasses were carefully dissected and the injection 
site of the subcutaneous tissue was exposed, inspected for any residues or for any gross 
inflammation, and photographed.   
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Table 2-2. Buprenorphine sustained release formulations tested in rats. 
 
Formulation Solvent Concentration of Buprenorphine (mg/g) 
Dose 
(mg/kg) 
R1 TBC  3.08  1.5 
R2 TBC  5  2.25 
R3 TBC  8.5  5 
 
 
 
 
Table 2-3. Buprenorphine sustained release formulations tested in mice. 
 
Formulation Solvent Concentration of Buprenorphine (mg/g) 
Dose 
(mg/kg) 
M1  TBC 3.9 8.9 
M2  TBC 0.87 2.2 
M3  TBC 0.44 1.1 
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2.2.5.4. PK and PD studies of buprenorphine in mice after subcutaneous injection of 
buprenorphine sustained release formulations  
 
Based on the results from rat studies, three buprenorphine formulations (Table  
2-3) were selected, prepared and tested in mice. Approximately 50 µL of buprenorphine 
solutions were administered subcutaneously in mice using 25-gauge needles. The 
syringes were weighed before and after subcutaneous administration of the solutions, and 
the exact weight of the buprenorphine solution administered to each mouse was noted.    
 
At predetermined time points after the administration, the analgesic activity of 
each formulation was evaluated via tail flick method in five mice and the average 
analgesic effect at each time point was reported as the Percentage of Maximum Possible 
Effect (%MPE). Immediately after the PD study, blood samples (0.6~1 mL) were 
collected by cardiac puncture method and placed in 1.5 mL heparinized centrifuge tubes. 
Then the mice were sacrificed by cervical dislocation under isoflurane anesthesia. The 
injection sites of the subcutaneous tissue were carefully dissected, exposed, inspected for 
any gross inflammation, and photographed for any residues. The collected blood samples 
were immediately centrifuged at 14K rpm for 15 min and plasma samples were stored at -
20ºC until further analysis for drug content using the validated LC/MS/MS method. The 
average plasma concentration at each time point was reported.  
 
 
2.2.5.5. Toxicity evaluation of citric acid esters in rats  
 
Approximately 200 µL of each of the sterilized citric acid esters (TEC, ATEC, 
TBC and ATBC) or normal saline were subcutaneously administered to four male SD 
rats. The animals were monitored for signs of toxicity and were weighed daily. Their 
eating and drinking habits were also closely monitored.  
 
 
2.3. Results and Discussion 
 
 
2.3.1.   Validation of analytical methodology 
 
 
2.3.1.1. Validation of HPLC assay for in vitro studies 
 
The standard curves of Method 1 and Method 2 are listed.  
 
 The standard curve of method 1 was: Peak area = 405278 * C (μg/mL)  
+ 29.27 (R = 0.9997) 
 The standard curve of method 2 was: Peak area = 114685.7 * C (μg/mL)  
- 289.9 (R = 0.9998) 
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Tables 2-4 and 2-5 show the intra- and inter-day variations of Methods 1 and 2 
respectively. The results show that both methods were reproducible and accurate. The 
samples obtained from solubility studies and dissolution studies were analyzed using 
HPLC Method 1. A narrow and sharp buprenorphine peak (retention time was 4.30 min) 
was obtained with the C-18 column and the number of theoretical plates (N) for 
buprenorphine was around 2,200. The Lower Limit of Detection (LLOD) of the assay for 
buprenorphine was 20 ng/mL. The LLOQ of the assay was 42 ng/mL. The samples from 
stability studies were analyzed using HPLC Method 2. A narrow and sharp 
buprenorphine peak (retention time was 3.8 min) was obtained with the silica-gel column 
and the column efficiency for buprenorphine (N) was approximately 6,000. The Lower 
Limit of Quantification (LLOD) of the assay was 12 ng/mL. The LLOQ of the assay was 
29 ng/mL. There was no interference between the buprenorphine and solvents peaks. 
 
 
2.3.1.2. Validation of LC-MS/MS assay for in vivo studies 
 
No significant interference was observed from the endogenous compounds at the 
retention times of the analytes using the optimized LC-MS/MS conditions. Moreover, the 
chromatographic retention times of both buprenorphine and buprenorphine-D4 were 5.1 
min and showed symmetrical peak shapes. The standard curve of buprenorphine was 
linear (Equation 2-2, R = 0.9998) in the entire range of the standard solutions (0.4 
ng/mL to 250 ng/mL):  
 
  C  0.02024  0.01135AUC
AUC
inebuprenorph
D4-inebuprenorph
inebuprenorph   (Eq. 2-2) 
 
where AUCbuprenorphine and AUCbuprenorphine-D4 are peak area of buprenorphine and 
buprenorphine-D4, respectively, and Cbuprenorphine is the concentration of buprenorphine. 
 
The LLOD of the assay for buprenorphine was 0.01 ng/mL and the LLOQ of the 
assay for buprenorphine was 0.4 ng/mL. The intra-day and inter-day variations of the 
assay developed for the in vivo studies are shown in Table 2-6.  The results showed that 
the developed assay was reproducible and accurate. 
 
 
2.3.2.  In vitro studies 
 
In order to test the effect of the hydrophobic vehicle with the varying 
hydrophilicity/lipophilicity on the drug release, nine vehicles were tested in solubility and 
stability studies. PEG 400, TEC, ethyl benzoate, ATEC, benzyl benzoate, TBC, ATBC, 
soybean oil and corn oil have different hydrophilicity and lipophilicity, and have been 
applied in pharmaceutical products. PEG 400 96 is member of polyethylene glycol family. 
It is a clear, colorless or slightly yellow-colored, viscous liquid. It is widely used in a 
variety of pharmaceutical products, such as parenteral, topical, ophthalmic, oral and 
rectal preparations. Intraperitoneal LD50 of PEG 400 is 10.0 g/kg for mouse and 9.7 g/kg 
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Table 2-4. Intra-day (n = 3) and inter-day (n = 3) variation of the assay 1. 
 
Buprenorphine Concentration 
(μg /mL) 
Intra-day RSD 
(%) 
Inter-day RSD 
(%) 
0.038 5.82 3.4 
0.076 3.52 9.3 
0.38 0.41 6.4 
7.6 0.51 6.2 
                     38 0.53 4.6 
 
 
 
 
Table 2-5. Intra-day (n = 5) and inter-day (n = 3) variation of the assay 2.  
 
Buprenorphine Concentration 
(μg/mL) 
Intra-day RSD 
(%) 
Inter-day RSD 
(%) 
0.03 15.0 NA 
0.12 4.7 4.8 
0.29 3.1 4.5 
1.17 1.4 2.1 
5.85 5.0 1.0 
 
 
 
 
Table 2-6. Intra-day and Inter-day variation of the LC-MS/MS assay (n=3). 
 
Buprenorphine Concentration 
(ng/mL) 
Intra-day RSD  
(%) 
Inter-day RSD  
(%) 
0.3654 12.8 14.0 
3.654 1.8 3.2 
49.54 0.5 4.0 
104.4 0.2 3.0 
195.75 0.4 2.5 
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for rat. Intravenous LD50 is 9.7 g/kg for rat. The cLogP value is - 4.8 and it is 
hydrophilic solvent. Triethyl citrate (TEC) 96 is a clear, viscous, odorless, and practically 
colorless, hygroscopic liquid with cLogP value of 1.45. It has been used as plasticizer in 
film coating. It has favorable safety profile and good stability. TEC has been accepted as 
a direct food additive by the U. S. Food and Drug Administration. LD50 is 5.9 g/kg in 
rats after subcutaneous administration and 1.75 g/kg in mice after intraperitoneal 
administration. Ethyl benzoate is a colorless liquid with cLogP values of 2.73. It is a 
component of some artificial fruit flavors. Oral LD50 for rat is 2.1 g/kg. Acetyl triethyl 
citrate (ATEC) 96  is a clear, odorless and colorless oily liquid with cLogP value of 3.73. 
It is generally regarded as a nontoxic and nonirritating material. Oral LD50 in rats is 7.0 
g/kg. Intraperitoneal LDso in mouse is 1.15 g/kg. FDA has approved its pharmaceutical 
use as a plasticizing agent in coating. Benzyl benzoate96 is a clear, colorless, oily liquid 
with a slightly aromatic odor with cLogP value of 3.97. It is used as a solubilizing agent, 
plasticizer and nonaqueous solvent in intramuscular injections at concentrations of 0.01–
46.0% (v/v) in pharmaceutical products. It is also used as a solvent and fixative for 
flavors and perfumes in cosmetics and food products. Besides, it is as a topical 
therapeutic agent in the treatment of scabies and therapeutically as a parasiticide in 
veterinary medicine.  Oral LD50 is 1.4 g/kg for mouse and 0.5 g/kg for rat. Tributyl 
citrate (TBC) 96  is a clear, odorless, practically colorless, oily liquid with cLogP value of 
4.68. It is considered as chemically inert and safe material. FDA has approved its 
pharmaceutical use as a plasticizing agent in coatings. Oral LD50 in rats is more than 30 
mL/kg. Intraperitoneal LD50 in mouse is 2.9 g/kg. Acetyl tributyl citrate (ATBC) 96  is a 
clear, odorless, practically colorless, oily liquid with cLogP value of 6.92. It is used in 
oral, topical pharmaceutical formulations and films intended for direct food contact. It is 
generally regarded as a relatively nontoxic and nonirritating material. Intraperitoneal 
LD50 for mouse is more than 4 g/kg and oral LD50 for rat is more than 31.5 g/kg. The 
skin irritation testing in rabbits showed that neither ATEC nor ATBC induced skin 
irritation.95 Soybean oil96 is a clear, pale-yellow colored, odorless or almost odorless 
liquid with a bland taste. It is used in cosmetics, pharmaceutical products and as bath 
additive to treat dry skin. In pharmaceutical products, it is used in parenteral nutrition 
vehicles for the oral and intravenous administration of drugs, and has been used in drug 
delivery systems such as liposomes, microspheres, emulsions, self-emulsifying systems, 
emulsions, nanoemulsions, and nanocapsules, solid-in-oil suspensions, and multiple 
emulsions. The intravenous LD50 is 22.1 g/kg for mouse and 16.5 g/kg for rat. 
 
 
2.3.2.1. Equilibrium solubility studies 
 
Table 2-7 lists the solubility of buprenorphine base in different solvents. It is 
apparent from the table that the drug has the highest solubility in ethyl benzoate, and 
lowest in corn oil and soybean oil at both 25 and 37C. The estimated minimum 
solubility was approximately 10 mg/mL calculated from the equation R0 = Css·CL, where 
the R0 is infusion rate, Css is plasma concentration at steady state, and CL is clearance. 
The clearance was from following PK study after intravenous injection of buprenorphine 
saline solution. The Css was obtained from the study after subcutaneous of buprenorphine 
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Table 2-7. Solubility of buprenorphine in different vehicles. 
 
@25ºC @ 37ºC Solvent 
(mg/mL)    Day 1   Day 2  Day 5  Day 1 Day 2  Day 5 
TBC 27.2 ± 1.7 28.5 ± 0.2 28.0 ± 0.3 30.2 ± 0.2 30.3 ± 0.6 29.9 ± 0.7 
ATBC 18.9 ± 0.8 20.7 ± 1.6 20.0 ± 1.0 20.1 ± 0.8 22.5 ± 0.5 23.0 ± 1.1 
TEC 19.2 ± 0.3 18.6 ± 0.3 19.1 ± 0.9 20.7 ± 0.1 22.6 ± 0.8 21.3 ± 1.1 
ATEC 14.7 ± 0.2 14.9 ± 0.1 14.1 ± 0.6 16.2 ± 0.3 17.3 ± 0.4 17.3 ± 0.7 
Ethyl benzoate 95.7 ± 0.2 95.9 ± 1.4 95.8 ± 1.0 102.7 ± 1.0 113.8 ± 1.3 112.2 ± 1.7 
Benzyl benzoate 47.5 ± 1.0 47.0 ± 0.3 47.5 ± 1.3 48.3 ± 0.5 50.1 ± 0.3 49.4 ± 1.4 
PEG 400 20.2 ± 0.6 21.6 ± 0.2 20.6 ± 0.8 23.4 ± 0.7 24.9 ± 0.4 24.6 ± 0.4 
Soybean oil 10.1 ± 0.2 11.0 ± 0.1 10.4 ± 0.1 11.0 ± 0.3 10.6 ± 0.9 11.6 ± 0.6 
Corn oil 10.1 ± 0.7 11.3 ± 0.4 10.5 ± 0.3 11.0 ± 0.2 11.2 ± 02 10.8 ± 0.1 
 
Data are presented as mean ± SEM (mg/mL). 
n = 3. 
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saline solution in rats. The results of calculation showed that the solubility of all the 
tested vehicles was more than 10 mg/mL and met the requirement of minimum solubility. 
 
 
2.3.2.2. Stability studies 
 
Figure 2-1 and Table 2-8 show the short-term stability of buprenorphine base in 
different solvents.  It is apparent from the table that buprenorphine base was stable in all 
the solvents at 25ºC for at least 30 days, but was not stable in PEG 400, soybean oil, corn 
oil and ATEC at 40ºC for one month. Therefore, TEC, TBC, ATBC, ethyl benzoate, 
benzyl benzoate were selected for in vitro dissolution study. 
 
 
2.3.2.3. Dissolution studies 
 
Buprenorphine in the oil vehicles of TEC, ATEC, TBC, ATBC, ethyl benzoate, 
benzyl benzoate were selected for in vitro dissolution study. Buprenorphine in ATEC did 
not show the promising stability for one month, but it is one of the citric acid esters with 
moderate hydrophobicity and has the potential be used with other vehicle(s) in the 
combination formulation. Therefore, the in vitro release profile of buprenorphine in 
ATEC was also tested considering it was stable for 1 week at 40°C. Figure 2-2 shows the 
effect of different vehicles on drug release. The release rate did not follow the order of 
cLogP values, but it was evident from the figure that fastest drug release was observed 
from formulation prepared with most hydrophilic vehicle, TEC, and 57.2% drug release 
was detected at 120 hr. It was apparent from the figure that slowest drug release could be 
achieved from the formulations prepared with lipophilic vehicles, benzyl benzoate and 
TBC. Considering the LD50 of benzyl benzoate in rats (0.5 g/kg, oral) and mice (1.4 
g/kg, oral), TBC showed the larger safety margin of LD50 in rats (>30mL/kg, oral) and 
mice (2.9 g/kg, IP) and was selected as the vehicles for in vivo study.   
 
 
2.3.3.  In vivo studies 
 
 
2.3.3.1.  PK and PD studies in rats after intravenous injection of buprenorphine saline 
solution  
 
Figure 2-3a shows the analgesia measured by the tail flick test in rats after an i.v. 
administration of buprenorphine hydrochloride solution at the dose of 0.05 mg/kg. At 5 
minutes after the i.v. injection, 100% MPE was obtained.  Then the analgesia decreased 
to 50% MPE within 9 hours, and no analgesia was observed after 24 hours after drug 
administration. The plasma concentration of buprenorphine versus time profile after i.v. 
injection in rats at a dose of 0.05 mg/kg is depicted in Figure 2-3b. Buprenorphine 
plasma concentrations of 14.5 ng/mL were achieved within 5 minutes after the i.v. 
injection.  The concentration then rapidly decreased within the first 15 minutes, and then 
declined more slowly thereafter. The concentration of buprenorphine in plasma was less 
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Figure 2-1. Stability of buprenorphine in various solvents. 
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Table 2-8. Stability of buprenorphine base in different solvents. 
 
% Drug Remaining Solvent Time  (Week) 25°C 40°C 
0 100.0 ± 2.7 100.0 ± 2.7 
1 100.6 ± 1.1 95.8 ± 2.3 
2 100.0 ± 3.3 90.6 ± 2.5 
3 99.1 ± 5.6 79.0 ± 2.6 
PEG 400 
 
4 98.8 ± 1.0 73.8 ± 2.2 
0 100.0 ± 1.0 100.0 ± 1.0 
1 104.5 ± 1.2 99.4 ± 1.6 
2 101.7 ± 2.0 101.8 ± 1.2 
3 98.1 ± 0.3 95.8 ± 1.0 
TEC 
 
4 97.7 ± 0.7 97.4 ± 1.4 
0 100.0 ± 0.1 100.0 ± 0.1 
1 100.9 ± 1.6 99.5 ± 5.4 
2 98.2 ± 1.0 96.4 ± 0.4 
3 96.8 ± 1.5 91.6 ± 2.8 
ATEC 
 
4 94.9 ± 0.5 88.8 ± 3.8 
0 100.0 ± 3.8 100.0 ± 3.8 
1 108.6 ± 0.5 102.8 ± 1.9 
2 108.1 ± 2.3 106.5 ± 4.9 
3 104.1 ± 3.4 103.3 ± 5.1 
TBC 
4 104.9 ± 1.1 102.8 ± 6.1 
0 100.0 ± 2.9 100.0 ± 2.9 
1 102.5 ± 0.4 103.7 ± 1.0 
2 103.9 ± 1.1 107.2 ± 3.5 
3 101.0 ± 1.1 96.9 ± 0.4 
ATBC 
4 101.3 ± 0.3 101.3 ± 1.4 
0 100.0 ± 1.0 100.0 ± 1.0 
1 96.1 ± 2.2 93.7 ± 9.8 
2 98.7 ± 2.0 79.4 ± 1.7 
3 98.8 ± 0.6 53.1 ± 2.9 
Soybean oil 
4 94.8 ± 0.7 34.8 ± 8.6 
0 100.0 ± 2.1 100.0 ± 2.1 
1 95.5 ± 4.6 97.5 ± 6.9 
2 97.2 ± 1.8 96.7 ± 1.8 
3 96.8 ± 2.6 75.9 ± 4.4 
Corn oil 
4 96.4 ± 1.0 53.8 ± 4.5 
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Table 2-8.  (Continued). 
 
% Drug Remaining  Solvent Time (Week) 25°C 40°C 
0 100.0 ± 1.3 100.0 ± 1.3 
1 99.9 ± 0.7 98.3 ± 1.8 
2 101.3 ± 1.2 100.8 ± 4.3 
3 101.1 ± 6.6 102.5 ± 1.4 
Ethyl Benzoate 
4 99.6 ± 0.8 100.2 ± 1.5 
0 100.0 ± 0.9 100.0 ± 0.9 
1 99.6 ± 1.5 99.8 ± 1.9 
2 96.3 ± 0.6 99.7 ± 2.4 
3 103.8 ± 1.5 99.8 ± 2.9 
Benzyl Benzoate 
4 100.1 ± 1.7 100.4 ± 1.7 
 
Data are presented as mean ± SD. 
n = 3. 
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Figure 2-2. In vitro release profile of buprenorphine from oily formulations 
prepared with various hydrophobic vehicles. 
 
Each data point represents an average of three measurements.  
Standard deviation of three measurements is presented as error bars. 
Buprenorphine concentrations in the different oily solvents were 1.5%. 
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Figure 2-3. (a) Analgesic effect and (b) plasma concentration of buprenorphine in 
rats after a single intravenous injection of buprenorphine hydrochloride solution at 
the dose of 0.05 mg/kg. 
 
Each data point represents an average of six measurements.  
Standard deviation of six measurements is presented as error bars. 
Intensity of the tail flick tester during the experiment is 60%. 
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than the LLOQ of the assay after 6 hr after the i.v. injection. The PK parameters was 
calculated and listed in Table 2-9.  
 
 
2.3.3.2. PK and PD studies in rats after subcutaneous injection of buprenorphine 
sustained release formulations 
 
Figure 2-4b shows the effect of different doses (1.5 mg/kg, 2.25 mg/kg and 5 
mg/kg) on buprenorphine plasma concentrations in rats after a single subcutaneous 
injection of formulations prepared with TBC. It is apparent from the figure that drug 
release occurred in a controlled manner from the buprenorphine solution and 
buprenorphine plasma concentrations increased proportionately as the dose of the drug 
was increased from 1.5 to 2.25 to 5 mg/kg. At the dose of 5 mg/kg, buprenorphine 
solution was able to achieve average Cmax of 22 ng/mL at 12 hours and maintain the 
average plasma concentrations above 7.8 ng/mL for 5 days. The average Cmax was 12 
ng/mL at 9 hours in rats that received buprenorphine solution at the dose of 2.25 mg/kg 
dose. The solution was able to maintain the average plasma concentration above 3.4 
ng/mL for 120 hours (5 days). Meanwhile, the average Cmax was 3.4 ng/mL at 6 hours in 
the rats administered with buprenorphine solution at the dose of 1.5 mg/kg dose.  The 
solution was able to maintain the average plasma concentration above 2.3 ng/mL for 120 
hours (5 days). 
 
The pharmacology profile of buprenorphine has the character of bell-shaped12,13,87 
dose-response curve for the antinociceptive action. The exact reason is not clarified and 
the possible reasons could be 2-receptor model and noncompetitive autoinhibition.16,87,97 
The peak of the dose-response curve was found to be occurred at a dose of 3 mg/kg in the 
rat tail dip test using water at 45°C or 55°C as the noxious stimulus.7 Figure 2-4a 
indicates that the best analgesia is achieved at the dose of 1.5 mg/kg. More than 55.1% 
MPE analgesia was maintained for 72 hours after administration. Then the analgesia 
declined to 20.1% MPE at 121 hours. The results shows that maintenance of higher 
plasma concentrations may not be necessary for achieving and maintaining better 
analgesia for a longer prolonged period of time.  
 
 
2.3.3.3. In vivo evaluation of buprenorphine sustained release formulations in mice 
 
Figure 2-5 shows the effect of varying buprenorphine doses (1.1 mg/kg, 2.2 
mg/kg, 8.9 mg/kg) on analgesia and buprenorphine plasma concentrations in mice after a 
single subcutaneous injection of formulations prepared with TBC (Table 2-3). It is 
apparent from the Figure 2-5a that there is no significant difference in the maintenance 
of analgesia for up to 48 hours after injecting either 8.9 or 2.2 mg/kg dose, and greater 
than 52.7% analgesia was maintained for 48 hours after administering either doses of 
buprenorphine. Then the analgesia declined to 49% MPE at 72 hours (3 days) and 31% 
MPE at 120 hours (5 days) after injecting 8.9 mg/kg dose. After injecting 2.2 mg/kg dose, 
the analgesia declined to 30% MPE at 72 hours (3 days) and 17% MPE at 120 hours (5 
days). Meanwhile, approximately 98% MPE - initial high analgesia was achieved at 3 
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Table 2-9. PK parameters of buprenorphine in rats after a single intravenous 
injection at the dose of 0.05 mg/kg.  
 
t0.5  
(hr) 
Vss  
(L/kg) 
Cl  
(L/hr/kg) 
0.59 ± 0.11 3.60 ± 0.63 4.89 ± 0.67 
 
Data are presented as mean ± SD. 
n = 6. 
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Figure 2-4. Effect of varying buprenorphine dose on (a) analgesia and (b) 
buprenorphine plasma concentration in rats after a single subcutaneous injection of 
the formulations prepared with TBC. 
 
Each data point represents an average of n measurements.  
Standard deviation of the measurements is presented as error bars. 
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Figure 2-5. Effect of doses on (a) analgesia (n=5) and (b) buprenorphine plasma 
concentrations in mice after subcutaneous injection of formulations.  
 
Each data point represents an average of the measurements.  
Standard deviation of the measurements is presented as error bars. 
Intensity of the tail flick tester during the experiment is 30%. 
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hours after a single subcutaneous injection of 1.1 mg/kg dose. Then the analgesia 
declined to 57.5% MPE at 24 hours (1 day) and 13% MPE at 120 hours (5 days). 
 
Figure 2-5b shows that buprenorphine plasma concentrations increased 
proportionately as the dose of the drug increased from 1.1 to 2.2 to 8.9 mg/kg. For the 1.1 
mg/kg dose, the average Cmax was 6.2 ng/mL at 3 hours, and the average plasma 
concentration was maintained above 1.4 ng/mL for 24 hours and above 0.3 ng/mL for 3 
days. For the 2.2 mg/kg dose, the average Cmax was 10.2 ng/mL at 3 hours, and the 
average plasma concentrations was maintained above 0.8 ng/mL for 3 days and above 0.1 
ng/mL for 5 days. For the 8.9 mg/kg dose, the average Cmax was 35.9 ng/mL at 3 hours, 
and the average plasma concentration was maintained above 2.5 ng/mL for 5 days in the 
animals. No significant difference in the maintenance of analgesia was found at the doses 
of 8.9 and 2.2 mg/kg for up to 48 hours after injection, although the drug plasma 
concentration and AUC of 8.9 mg/kg dose is significant higher than those of 2.2 mg/kg 
dose. This shows that the relationship between drug plasma concentrations and analgesia 
response are not linear. In this study, 30.1% MPE can be maintained for 3 days with the 
drug plasma concentration of 0.8 ng/mL. The bell-shaped dose response curve may 
explain it and has been demonstrated in mice after subcutaneous injection of 
buprenorphine hydrochloride.98  
 
 
2.3.3.4. Typical photographs of the subcutaneous tissue at the injection site after 
administration of different formulations in rats and mice 
 
The toxicity and skin irritation studies of citric acid esters including ATEC and 
ATBC showed tested citrated were safe to use.95 Although there was absence of irritation 
data on TBC, it is reasonable to expect the low or no irritation properties of TBC because 
of the structure similarity with ATBC. The injection site views after subcutaneous of the 
buprenorphine formulations R1 to R3 and M1 to M3 in rats and mice were similar. 
Figure 2-6a shows the subcutaneous injection site of the rat after administration of 
buprenorphine formulation R1 at day 5. The figure indicated that no formulation 
remained at the injection site at day 5 after a single subcutaneous administration of 
buprenorphine formulations prepared with TBC. In addition, no obvious inflammation 
was observed in most of tested rats at the injection sites. The sign of mild inflammation 
was observed in 2 out of 15 tested rats. Figure 2-6b also indicated that no formulation 
remained at the injection site on day 5 after the administration of formulation M2 in mice. 
Moreover, no obvious inflammation was observed in mice at the injection sites.   
 
 
2.2.3.5. Evaluation of toxicity of citric acid esters in rats 
 
Figure 2-7 shows the body weight changes of the rats with time after a single 
subcutaneous injection of 200 µL of sterilized citric acid esters (TEC, ATEC, TBC and 
ATBC) or normal saline solution. No systemic toxicity or significant body weight change 
(P = 0.946, one-way ANOVA) was observed in the rats injected with the citric acid esters 
compared to those injected with normal saline. Also no abnormal eating and drinking  
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(a) 1.5 mg/kg (Rat) at day 5  (b) 2.2 mg/kg (Mouse) at day 5 
 
 
Figure 2-6.  Typical injection site after subcutaneous administration of 
buprenorphine formulation prepared with TBC in (a) rats and (b) mice at day 5. 
 
Doses in the rat and mouse studies are 1.5 mg/Kg and 2.2 mg/Kg, respectively. 
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Figure 2-7. Body weight changes of rats after subcutaneous administration of 
different citric acid esters or normal saline solution. 
 
Each data point represents an average of four measurements.  
Standard deviation of four measurements is presented as error bars.  
The P value is 0.946. 
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habits were observed. This is in accord with the results of acute and chronic toxicity 
studies of TEC, ATEC, TBC and ATBC which indicated that all four tested citric acid 
esters would not cause damage to the liver, kidney, lungs and spinal cord for the tested 
animals.99,100 
 
 
2.4. Conclusions 
 
Oral administration route is the most convenience delivery method for human, but 
it, such as putting analgesic in the water for the rodents, runs the risk of inaccurate dosing 
and that of degradation due to hydrolysis.101  Therefore methods for analgesic delivery to 
rodents are primarily limited to parenteral rather than oral delivery. 
 
Animal welfare regulations require that analgesia should be provided whenever a 
procedure is performed or a condition is present that is likely to cause pain. Laboratory 
rats and mice are widely used in research and suffer the pain after the surgery. Opioid 
analgesics are the primary therapeutic agents used for moderate to severe pain.87 
Buprenorphine, butorphanol and morphine are three commonly used opioids. 
Buprenorphine had an intermediate analgesic effect and the longest duration (6 to 8 hrs in 
rats and 3 to 5 hrs in mice) compared to morphine (2 to 3 hrs)  and butorphanol (1 to 2 
hrs) in rats and mice.93 The Formulary for Laboratory Animals lists the recommended 
buprenorphine dose as 0.01-0.05 mg/kg (SC/IV, 2-3 times daily) for rats and 0.05-0.1 
mg/kg (SC, 2-4 times daily) for mice.  
 
Sustained release analgesic provides the advantages of accurate dosing, reducing 
the stress of frequent handling and injection, and improving the well-being of research 
animals. This hydrophobic delivery system has the advantages of easy preparation, 
simple sterilization by filtration, easy administration (including filling and injection), and 
cost efficiency. The use of a sustained-release analgesic hydrophobic formulation could 
decrease the frequency of handling and increase the welfare of animals at low cost. 
 
The solubility, stability and in vitro dissolution studies were performed in vitro to 
screen the hydrophobic vehicles in this study. Buprenorphine in TBC vehicle showed 
high solubility, good stability, and desired sustained drug release in vitro performance. In 
addition, TBC has been used widely in pharmaceutical products and the toxicity data 
supported that TBC was safe to use at tested amount. Therefore it was selected as the 
hydrophobic vehicle and tested in rats and mice at different doses. The dosing in PK 
studies was based on the calculation and prediction from a desired release profile. The 
PK and PD results showed that a simple long-acting controlled release delivery system of 
buprenorphine capable of maintaining analgesia in rats and mice for 3 to 5 days after a 
single subcutaneous administration was developed in this study.  
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CHAPTER 3.    A NOVEL IN VITRO DISSOLUTION MODEL FOR OILY 
FORMULATIONS: MODEL DESIGN, RELEASE MECHANISM, AND THE 
DEVELOPMENT OF LEVEL A IVIVC 
 
 
3.1. Introduction 
 
Current United States Pharmacopeia (USP) apparatus for in vitro release testing 
was designed mainly for oral and transdermal products. In contrast, there are no standard 
regulatory methods for parenteral sustained release products at present.69,70 Over the past 
decade, several methods have been attempted to describe drug release from parenteral 
products and the current in vitro release methods for parenterals might be divided into 
four broad categories: sample-and-separate,69,70 ultrafiltration,70 continuous flow 
methods,69,70 and dialysis techniques including rotating dialysis,71 dialysis sac,70 and 
microdialysis.70 The advantages and disadvantages of each method were discussed by 
Diane J. Burgess70 and Claus Larsen.69 In general, dialysis techniques are considered 
feasible for the study of drug release from the solutions and suspensions.102,103 Amongst 
these methods, the rotating dialysis cell model has been used to study drug release from 
oily depot solutions.71 It offers the advantages of reproducible results and fast distribution 
processes. But it has been shown to establish an in vitro-in vivo correlation for just one 
particular formulation.104 In addition, commercially available Float A Lyzer® dialysis 
tubes can be used as an alternative dialysis model.  In contrast to the rotating dialysis cell, 
it works at much less intensive stirring conditions, resulting in lower drug transport 
rates.105  
 
A successful in vitro dissolution model needs to differentiate the variants within 
the appropriate formulations with similar drug release mechanism, and any changes with 
respect to process or manufacturing site. Level A IVIVC can be used to set the critical 
dissolution specifications and as a surrogate for in vivo bioequivalence.103 As regards to 
quality control as well as formulation development purposes,69,106 it is still highly 
desirable to a develop suitable in vitro release model for parenteral products with the 
characters of Level A IVIVC and elaboration on drug release mechanism. The 
development of IVIVC for parenteral products is more difficult than oral dosage forms. 
Only a few publications had success on IVIVC for parenteral products107 and very few 
examples of IVIVC being developed from more than one formulation.107 In addition, for 
most examples in which IVIVC was stated for parenterals, the mathematical models that 
describe the drug release have not been provided.107 So far there is no successful in vitro 
dissolution method with the character of Level A IVIVC exists at present for parenteral 
oily formations. In general, it is accepted that the process of development and validation 
of IVVIC for parenterals could follow the same as modified release (MR) oral 
products107. The principles of FDA IVIVC MR guidance108 for oral products were used to 
develop level A IVIVC for parenterals in this study.  
 
Long-acting buprenorphine controlled release formulations were developed and 
tested in this study in order to verify the new dissolution model. The purposes of this 
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study are to design, develop and validate the novel dissolution model with the character 
of level A IVIVC and to elucidate the drug release mechanism of this model.  
 
 
3.2.  Materials and Methods 
 
 
3.2.1. Materials 
 
Buprenorphine was obtained from Diosynth Inc. (Morrisville, NC).  Tributyl 
citrate (TBC) and acetyltributyl citrate (ATBC) were obtained from Morflex, Inc. 
(Greensboro, NC). Heparinized Microvette tubings (Microvette CB 300 LH) were 
purchased from Sarstedt (Newton, NC). Sodium dodecyl sulfate (SDS) and acetonitrile 
(ACN) were purchased from Sigma-Aldrich (St. Louis, MO).  
 
 
3.2.2. Animals 
 
Approximately 300 g Sprague Dawley male rats (Charles River Labs, 
Wilmington, MA) were used in this study. The animals were randomly assigned and 
group-housed in polycarbonate caging with ad libitum access to food and water. All 
animal experiments were conducted according to protocols approved by the Institutional 
Animal Care and Use Committee (IACUC).  
 
 
3.2.3. Softwares 
  
Excel 2003 (Microsoft Office, Redmond, WA), WinNonlin (Pharsight 
Corporation, Cary, NC), SPSS 17.0 (SPSS Inc., Chicago, IL), and Stella 9.0 (isee 
systems, Inc., Lebanon, NH) were used to process the data generated in this study. 
 
 
3.2.4. Analytical methodology for in vitro and in vivo studies 
 
 
3.2.4.1. Analytical methodology for in vitro studies – HPLC/fluorescence analysis  
 
HPLC method validation developed to quantitate buprenorphine in samples 
obtained from in vitro studies has been discussed in Chapter 2. Briefly, discovery C-18 
column (2.1 x 100 mm) (Supelco, Bellefonte, PA) was used. The mobile phase was 
composed of a mixture of 51 mM KH2PO4 buffer and acetonitrile (ACN) (45:55, v/v) 
with the final pH 6.65 adjusted by 10N NaOH solution. The oven temperature was 40°C 
and the flow rate was 0.3 mL/min. The total run time was 6 minutes. Buprenorphine was 
detected with fluorescence detector at λExitation = 292 nm and λEmission = 350 nm.  
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3.2.4.2. Analytical methodology for in vivo studies – LC-MS/MS method 
 
Validation of LC/MS/MS method has been discussed in Chapter 2 to quantify the 
concentrations of buprenorphine in plasma samples obtained from in vivo studies. 
Briefly, LC/MS/MS system consisted of Shimadzu HPLC systems, a HILIC silica 
column (5 m, 150 × 4.6 mm) with a guard column (10 × 2.1 mm) (Waters Inc., Milford, 
MA), and API 4000 tandem triple quadrupole mass spectrometer (Applied Biosystems, 
Foster City, CA). Solution A (ACN : water : formic acid (4.95:95:0.05, v/v/v) with 2 mM 
ammonium formate) and solution B (ACN : water : formic acid (95:4.95:0.05, v/v/v) with 
2 mM ammonium formate) were used. The time program of the gradient method started 
with 90% of Solution B followed by decreasing linearly from 90% to 40% within 3.5 
minutes. Then it immediately increased to 90% and maintained at 90% for 2 minutes.  
The concentration of Solution B was further decreased linearly from 90% to 40% within 
0.5 minute, linearly increased to 90% within 0.5 minute and maintained at 90% for 4 
minutes. The column was operated at room temperature and the flow-rate of the mobile 
phase was 0.5 mL/min. Ion transition of 468.3 to 468.3 and 472.3 to 472.3 were selected 
for buprenorphine and buprenorphine-D4 detection, respectively.   
 
 
3.2.5. Formulation preparation 
 
An appropriate amount of buprenorphine base powder was accurately weighed 
and dispersed into an appropriate amount of solvent(s) (Table 3-1) in 20 mL glass 
scintillation vials. The subsequent suspension was sonicated under 25ºC until all drug 
powder was dissolved. The final solution was obtained by filtering the above solution 
through a 0.22 μm syringe filter in a sterile hood and then sealed. The drug concentration 
was verified by HPLC method. Formulation 3-1b and 3-2 were tested in rats for IVIVC 
development and all prepared formulations were tested in the designed dissolution model 
for different purposes.  
 
 
3.2.6. In vitro tests 
 
 
3.2.6.1. In vitro dissolution model design 
 
When the partition coefficient of the API is below approximately 10,000,109 it is 
expected that drug molecules transport from the injection site to the systemic circulation 
by two steps after intramuscular or subcutaneous administration of oily solutions.103 Drug 
molecules (1) diffuse out of the oily vehicle into the aqueous tissue fluid followed by (2) 
transporting through the tissue fluid to the systemic circulation. Except in-situ forming 
gels,103 partition between the oily vehicle and the aqueous fluids is the rate limited step 
and absorption rate has little dependence on vehicle viscosity.103,110 The cylinder-in-
basket (CIB) apparatus (Figure 3-1) was designed and developed based on this drug 
absorption mechanism, The CIB apparatus consists of a cylinder, a USP standard 1-Liter 
vessel, a USP standard cylindrical basket (40-mesh basket in this study), a USP standard
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Table 3-1. The formulations tested in the dissolution model development study. 
 
Concentration of 
Buprenorphine Tested in Dose  Formulation Solvent(s) 
% (w/w) In Vitro In Vivo (mg/kg) 
3-1a TBC 0.3 x   
3-1b TBC 0.5 x x 3 
3-1c TBC 1.5 x   
3-1d TBC 3 x    
3-2 ATBC 0.5 x x 3 
3-3a TEC:ATEC:TBC 1:1:1 (v/v/v) 0.5 x x 3 
3-3b TEC:ATEC:TBC 1:1:1 (v/v/v) 1.3 x   
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  (a) (b) 
 
Cylinder # #1 #2 #3 #4 #5 #6 
Height (mm) 12.3 12.3 12.3 24.6 24.6 24.6 
Diameter (mm) 12.5 15.0 17.5 12.5 15.0 17.5 
 
 
Figure 3-1. (a) Cylinder and (b) cylinder-in-basket (CIB) apparatus for in vitro dissolution study. 
 
 
 
Height 
5.00 mm
20.00 mm 
Diameter 
 
 
 
 
Cover 
 
1-Liter vessel 
 
Dissolution medium 
 
 
Paddle 
 
Cylindrical basket (40 mesh) 
 
 
Loaded formulation 
Cylinder 
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paddle, a USP standard dissolution apparatus (Hanson SR8PLUS Dissolution Test 
Stations, Hanson Research Corp.) and an AutoPlus Autosampler (Hanson Research 
Corp.). There are two compartments in this CIB model: the small compartment inside the 
basket and the bulk compartment outside the basket. The solution in the small 
compartment mimics the body fluid and the media in the bulk compartment mimics the 
systemic circulation. After loading the formulation into the cavity of the cylinder, the 
drug molecules were assumed to diffuse into the small compartment followed by 
transporting to the bulk compartment. The basket was designed to protect the oily vehicle 
out of the vigorous convection in the bulk compartment and mimic the biological barrier. 
During the experiment, the oily vehicles were assumed to maintain the constant surface 
area which benefited the mechanism study. Six different Teflon cylinders (Figure 3-1) 
were designed, prepared and tested in this study for different purposes. Except the studies 
to explore the effect of cylinder surface area and height, the cylinder #5 was used in the 
rest studies. 
 
 
3.2.6.2. Partition coefficients 
 
The partition coefficients of buprenorphine between the oily vehicles and 
dissolution medium were performed in triplicate. According to preliminary studies, 
solutions of drug in aqueous phase-saturated oily vehicles were allowed to equilibrate 
with the oil phase-saturated aqueous buffers in the incubator at 100 rpm and 37 ± 0.5°C 
for at least 48 hr. Drug concentrations in the aqueous phase were directly measured by a 
validated HPLC method. The drug content in the oily phase was determined by diluting 
100-fold with ACN : water (70:30, v/v), followed by drug concentrations analysis using 
HPLC method.  The partition coefficients were calculated according to the Equation 3-1. 
 
 
aq
oil
C
CP   (Eq. 3-1)
 
        
where Coil and Caq represent the drug concentration in the oily phase and the aqueous 
phase at the equilibrium state, respectively.  
 
 
3.2.6.3. Short-term stability studies 
 
Short-term stability of buprenorphine in the dissolution medium at 25°C and 40°C 
was evaluated within 5 days. The drug concentration in the tested samples was equal to 
the value of the maximum amount of drug in tested formulation dissolved in 900 mL 
dissolution medium. The sample solution in a 20 mL scintillation vial wrapped securely 
with para-film was stored in ovens at 25 ± 0.5 °C and 40 ± 0.5 °C. The study was 
performed in triplicate at each time point. Drug concentration in the sample at time 0 was 
used as the reference. The drug content in the samples was tested at predetermined time 
points using HPLC method. The length of each drug stability study was different and the 
last time point of the stability study was selected as same as that in dissolution study.  
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3.2.6.4. In vitro release studies 
 
The tested formulation was loaded into the cavity of the cylinder followed by 
covering with the USP basket (40-mesh). The cylinder-in-basket kit was then transferred 
to the center bottom of a 1-Liter dissolution vessel. The dissolution medium was carefully 
loaded into the vessel at the rate of 7 mL/sec using a modified Hanson Media Mate 
(Hanson Research Corp.). The paddle blade stirrer was then inserted into the apparatus 
and located on the top of the basket. The distance between the top of the basket and the 
bottom of paddle blade was adjusted. Except the study on the effect of paddle distance, 
the distance was set at 2 cm. The vessels were covered with a special designed lid and 
tightened with laboratory para-film in order to avoid evaporation of the medium. The 
paddle and dissolution medium were varied for different purposes and will be specified in 
the discussion section. Experiments were conducted by triplet. During the dissolution 
experiment, samples (1 mL) in bulk dissolution medium were withdrawn from each 
vessel at predetermined time points. After sampling, 1 mL blank dissolution medium was 
refilled into the bulk dissolution medium. Drug content of the samples was measured by a 
validated HPLC method. The pH of dissolution medium was adjusted by hydrochloride 
and sodium hydroxide. The ion strength of dissolution medium calculated by Debye–
Hückel equation was adjusted by sodium chloride and kept at 0.13. The percentage of 
drug released from the solutions was calculated according to the Equation 3-2. 
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where Vs is the sampling volume (1 mL in this study) at different time points and Vb is 
the volume of total dissolution medium; Cn and Cn-1 represent the drug concentration in 
sample n and n-1;  Mtotal is the total amount of drug in the tested formulation. 
 
 
3.2.6.5. Discriminating power of the dissolution test 
 
The drug release profile can be predicted from proposed equation. The 
discriminatory power of the dissolution test was used to evaluate the difference between 
predicted and experimental dissolution profiles. The predicted and experimental 
dissolution profiles were compared using two methods: the difference factor (f1) and the 
similarity factor (f2). The f1 factor111 measures the percent difference between two curves 
over all time points and can be calculated by Equation 3-3. The value of f1 factor is zero 
when the test and drug reference profiles are identical and proportionally increases as the 
dissimilarity of the two dissolution profiles increases. 
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where n is the number of time points, Rt and Tt are the percent dissolved of the reference 
and test product, respectively, at each time point. The predicted dissolution profile was 
used as the reference. 
 
The f2 factor111 is a logarithmic reciprocal square root transformation of the sum 
of squared error and measures the differences between the test and the reference products 
over all time points and can be calculated by Equation 3-4. This factor is 100 when the 
test and reference profiles are identical and decreases as the similarity of the two 
dissolution profiles decreases.  
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3.2.7. IVIVC development 
 
 
3.2.7.1. In vitro studies for IVIVC development 
 
The in vitro drug release of formulation 3-1b and 3-2 were conducted in CIB 
dissolution model. The loading volume (~ 0.2 mL) of the oily formulation was the same 
with the injection volume in rat studies. The mixture of 15% (v/v) n-propyl alcohol (nPA) 
in Phosphate buffered saline (PBS) solution with 0.15% (w/v) sodium dodecyl sulfate 
(SDS) at pH6.0 was selected as the dissolution medium. The paddle speed was set at 50 
rpm and cylinder #5 was utilized. The amount of drug release at different time point, Mt, 
was evaluated by validated HPLC method. The linear correlation was explored by SPSS 
software. The percentage drug release was calculated by Excel. 
 
 
3.2.7.2. In vivo evaluation of buprenorphine solutions in rats for IVIVC development 
 
FDA recommends that two or more formulations with different drug release rate 
should be used to develop level A IVIVC.108 The data generated in rat studies after 
subcutaneous injection of formulation 3-1b and 3-2 (Table 3-1) were tested in this study. 
Formulation 3-1b or 3-2 (~ 200 µL) were subcutaneously administered into male Sprague 
Dawley (SD) rats (four rats/group) using 23-gauge needle and the syringes were weighed 
before and after administration. The exact weight of the buprenorphine solution 
administered was calculated based on the weight. Blood samples (~ 0.2 mL) were 
withdrawn by saphenous vein and collected in heparinized Microvette tubings at 
predetermined time points within two weeks. The collected blood samples were 
immediately centrifuged at 14K rpm for 7 min and plasma samples were stored at -20°C 
until further analysis. The plasma samples were processed and analyzed for drug content 
using the validated LC/MS/MS method. The average plasma concentration at each time 
point was reported. 
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3.2.7.3.  Bioavailability of buprenorphine in rats  
  
An intravenous study was tested in rats to determine the PK parameters of 
buprenorphine at the dose of 0.05 mg/kg and described in Chapter 2. The PK parameters 
(Ke, AUC0-t, and AUC0-∞) were calculated by using WinNonlin non-compartment model. 
The terminal elimination rate constants (Ke) after i.v. administration were estimated with 
least-squares regression of values in the terminal log-linear region of plasma 
concentration–time curves. The areas under the curve (AUC) from time zero to last 
sampling time (AUC0-t) after drug administration were determined by the logarithmic 
trapezoidal rule. The area under the curve from time zero to infinity (AUC0-∞) was 
calculated as AUC0-t +Ct/Ke, where Ct is the last detected plasma concentration and t is 
the time. 
 
Buprenorphine saline solution was subcutaneously injected into four male 
Sprague Dawley (SD) rats at the dose of 0.05 mg/kg. The syringes were weighed before 
and after subcutaneous administration and the exact weight of the buprenorphine solution 
administered was calculated based on the weight. Blood samples (~ 0.2 mL) were 
withdrawn from the saphenous vein with a 25 gauge needle and kept in heparinized 
Microvette tubings at 0, 5, 15, and 30 min, and 1, 2, 4, 6 and 12 hr.  
 
The bioavailability (F) was calculated by Equation 3-5 after subcutaneous 
injection of buprenorphine saline solution at the dose of 0.05 mg/kg. 
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where AUCSC, AUCi.v. and DSC, Di.v. represent the AUC and dose after the subcutaneous 
or intravenous injection. 
 
 
3.2.7.4. Deconvolution method  
 
The fraction of drug absorbed in vivo (Fa) after subcutaneous injection of 
formulation 3-1b and 3-2 was determined using the Loo-Reigelman method by Equation 
3-6.112 The model-dependent pharmacokinetic parameters of K10, K12 and K21 used in the 
calculation were calculated using WinNonlin two-compartment model. The de-
convolution was accomplished on a spread-sheet in Excel. 
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where (XA)t, (XA)∞ and (Xp)t represent the amount of drug absorbed at time t, the amount 
of drug ultimately absorbed, and the amount of drug in the peripheral compartment at 
time t. Ct, K10 and Vc represent the plasma concentration at time t, the apparent first-order 
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elimination rate constant of the drug from the central compartment, and the apparent 
volume of the central compartment. AUC0-t and AUC0-∞ represent area under the plasma 
concentration-time curve from time zero to the last measurable concentration and from 
time zero to infinity. 
 
After the calculation of Fa, the drug release amount at different time point in vivo 
was calculated based on bioavailability and total amount injected. The linear correlation 
between Ln[Mtotal /( Mtotal-Mt)] and time was explored by SPSS software, where Mtotal is 
the total amount of the drug absorbed. 
 
 
3.2.7.5. IVIVC development and validation 
 
The data generated in the in-vitro and in-vivo studies and linear relationship 
between Fdiss and Fa of tested formulations were used in internal and external validation. 
The relationship between mean percent of drug dissolved in in-vitro dissolution study 
(Fdiss) and the mean fraction of drug absorbed in-vivo (Fa) was examined in this study. 
The Fdiss was determined using the CIB dissolution testing method and Fa was 
determined by Loo-Riegelman method. The linear regression analysis was applied to 
explore the relationship between Fdiss and Fa. The values of coefficient of determination 
(R2), slope and intercept were calculated, respectively.  
 
The internal predictability of the IVIVC was evaluated by comparing predicted 
plasma profiles with the actual plasma profiles of formulation 3-1b and 3-2. The 
prediction of the plasma drug concentration and AUC was accomplished using IVIVC 
toolkit of Stella 9.0 (isee systems, Inc.) software.113 The pK parameters of buprenorphine 
in rats, the linear relationship generated in IVIVC development, and the mean in-vitro 
dissolution data (Fdiss) of each examined formulation were input into the software. The 
observed and IVIVC model-predicted Cmax and AUC values for each formulation were 
used to access the predictability of the correlation. The percent prediction errors (%PE) 
for Cmax and AUC were used to evaluate prediction and calculated by Equations 3-7 and 
3-8.108 
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where Cmax(obs), Cmax(pred) and AUC(obs), AUC(pred) are the observed and IVIVC 
model predicted maximum plasma concentrations and AUC, respectively. 
 
 The external validation was accomplished by comparing predicted plasma profiles 
with the actual plasma profiles of formulation 3-3a.  The pK parameters of buprenorphine 
in rats, the linear relationship generated in IVIVC development, and the mean in-vitro 
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dissolution data (Fdiss) of the formulation were input into Stella to predict the drug release 
profile. The same dissolution conditions were applied in in-vitro study. The percent 
prediction errors (%PE) for Cmax and AUC were also used to evaluate prediction. 
 
 
3.3. Results and Discussion 
 
 
3.3.1. In vitro studies 
 
Unlike the solid formulations, the surface of the parenteral formulations is easy to 
be disrupted by other factors, such as agitation of the dissolution medium. The variance 
of the surface of the parenteral formulations is one of the major reasons caused the 
unpredictable drug release. According to the preliminary studies, the high variance could 
be generated on the steps of the loading of the dissolution medium and by the agitation of 
the dissolution medium. In this study, the Hanson Media Mate (Hanson Research Corp.) 
was used to load the dissolution media at the rate of 7 mL/sec. A special designed tubing 
was used to conduct the medium solution to the wall of the vessel during the loading 
process. In addition, the agitation generated by paddle in the bulk solution can cause the 
high variation of the surface of liquid formulation during the dissolution test. Therefore 
the effect of paddle position, paddle speed, and cylinder diameter were investigated by 
formulation 3-1c and dissolution medium of 10% (v/v) iso-propyl alcohol in PBS with 
0.05% SDS at pH 7.4 in this study. 
 
 
3.3.1.1. Effect of paddle position 
 
One of the major problems of in vitro dissolution model development for the 
parental formulations is the high variation generated during the experiment. In this CIB 
dissolution model, the basket was designed to protect the liquid formulation out of the 
effect by the agitation of the dissolution medium. The USP standard 40-mesh basket is 
selected to protect the liquid formulation. The distance (0.5 and 3 cm) between the bottle 
of paddle blade and the top of the basket was tested on the condition of high agitation 
(150 rpm) to explore the effect of the paddle position. Two cylinders, #5 and #6, with 
different diameter (15.0 mm and 17.5 mm) were tested. If the 40-mesh basket couldn’t 
protect the liquid formulation, the high variance was expected and the drug release rate 
tested in two different conditions with different distances should vary because of the 
different convection environment at the liquid/medium interface.  
 
Figure 3-2 shows the release profiles of buprenorphine from oily vehicle in the 
CIB dissolution model by changing the paddle location. The f2 values are 81.2/87.4 and f1 
values are 12.4/6.1 for the results generated from cylinder #5 and #6, respectively. It 
indicates that there is no significantly difference of the dissolution rate for the test 
formulation by changing the paddle position at 150 rpm. The drug release rate is not 
affected by the vigorous convection outside the basket under the tested formulation and 
conditions.  In addition, the less variance of dissolution results using CIB model was  
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Figure 3-2. The effect of paddle position on the release amount of buprenorphine 
in CIB dissolution model.  
 
n =3. 
Data are presented as mean ± SD (g). 
Tested formulation was formulation 3-1c.
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observed, which indicated that the 40-mesh basket can protect the oily phase from the 
vigorous convection in the bulk solution. 
 
 
3.3.1.2. Effect of paddle speed 
 
The agitation of the medium could be the other reason which causes the high 
variation in the CIB model, so the effect of paddle speed was explored at the levels of 
100 and 150 rpm.  Figure 3-3 shows that drug release rate is noticeably faster at 150 rpm 
than that observed at 100 rpm with low variance. This indicates that drug release rate 
increases at the higher speed. In the CIB dissolution model, it is expected that drug 
molecules first diffuse into the small compartment and then diffuse out from small 
compartment to the bulk compartment. Different paddle speed will affect the convection 
flow in the bulk media. Vigorous agitation can help drug concentration to achieve the 
equilibrium between the media inside and outside of the basket. Higher paddle speed is 
expected to give a more vigorous agitation and to achieve equilibrium in a shorter time, 
resulting in higher concentration gradient. Therefore, the drug concentration in the bulk 
media will achieve equilibrium faster and drug release at higher paddle speed gives faster 
release rate.  
 
 
3.3.1.3. Effect of cylinder height 
 
Two different sets of cylinders were used. The first set (cylinder #2 and #3) has 
the height of 12.3 mm with the diameter of 15 mm and 17.5 mm. The second set 
(cylinder #5 and #6) has the height of 24.6 mm with the different diameter. Other 
parameters of the cylinder are the same and the paddle speed during the dissolution study 
was set at 100 rpm. Figure 3-4 shows that the amount of drug release using the 12.3 mm 
height cylinder is faster than that using the 24.6 mm height cylinder. The volume of the 
cylinder with the height of 12.3 mm is less than that of the cylinder with the height of 
24.6 mm. When 12.3 mm height cylinder is covered with the basket, the volume of 
dissolution medium inside the basket (volume of small compartment in CIB model) is 
relatively larger than that using 24.6 mm height. When the same amount of drug is 
diffused out of the oil vehicle into the small compartment, the drug concentration in the 
small compartment will be relatively lower using 12.3 mm height cylinder compared to 
that using 24.6 mm height cylinder if the drug release rate is the same. And the 
concentration gradient will be relatively higher by using 12.3 mm height cylinder. 
Therefore the height of cylinder could affect the drug release rate and the cylinders with 
different height should be carefully selected for different purposes.   
 
 
3.3.1.4. Effect of diameter of cylinder 
 
After loading the oily formulation into the cavity of the cylinder, the surface area 
between aqueous phase and oily vehicle is assumed to the surface area of the cylinder  
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Figure 3-3. The effect of paddle speed on the release amount of buprenorphine in 
CIB dissolution model. 
 
n =3. 
Data are presented as mean ± SD (g). 
Tested formulation was formulation 3-1c. 
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Figure 3-4. The effect of cylinder height on the release amount of buprenorphine 
in CIB dissolution model. 
 
n =3. 
Data are presented as mean ± SD (g). 
Tested formulation was formulation 3-1c. 
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cavity. The cylinder #1, #2 and #3 with different surface area were used in this test and 
the paddle speed was set at 100 rpm. The cylinder diameter aggrandizement from 
cylinder #1, #2 to #3 also increased the exposed surface area between oil formulation and 
dissolution medium. Figure 3-5 shows that drug release rate increases with the cylinder 
surface diameter. By increasing the surface area of cylinder, more drug molecules can 
diffuse out of oily phase to the aqueous phase at unit time.  According to the Equation  
3-9, the slope was calculated by plotting Ln[C0V0/(C0V0-Mt)] versus time. The 
experimental release rates (Kapp) for each cylinder are 0.0321, 0.0463 and 0.0625 day-1, 
respectively, with the ratio of 0.69:1:1.35. The ratio of the surface area (πr2) of three 
cylinders is 0.69:1:1.36. The result is consistent with the Equation 3-9, which indicates 
the release rate is proportional to the surface area when there is no change in the other 
parameters. The derivation and details of Equation 3-9 will be discussed in Section 
3.3.2.1. 
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where C0 and V0 represent initial drug concentration and initial volume of loaded 
formulation. Mt represents the amount of drug at different time in aqueous phase. D, h 
and S represent diffusion coefficient, the length of diffusion layer, and oil–water interface 
area. The K is the ratio of D divided by h and Kapp  is the apparent rate constant. 
 
 
3.3.2. Drug release mechanism 
 
 Drug release mechanism in the CIB dissolution model was explored in this study. 
The in vitro CIB model was designed to mimic the in vivo drug absorption mechanism 
after subcutaneous or intramuscular injection. There are two compartments in the CIB 
model. The small compartment (1) inside the basket and the large compartment (2) 
outside the basket mimic the body fluid at the injection site and the systemic circulation, 
respectively. In order to explore drug release mechanism in CIB model, the assumption 
was made that drug molecules in the oily vehicle diffused into the aqueous dissolution 
medium and the kinetic equilibrium can be achieved instantly at the interface between the 
oily vehicle and dissolution medium, although the equilibrium between the oily phase 
and the bulk solutions may take a few hours to reach in the partition coefficient test. 
Therefore the drug concentration at the interface between the oily vehicle and dissolution 
medium can be calculated by Equation 3-10. 
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where Ctoil and Ctaq-inter are the drug concentration at different time points in the oily 
phase and the aqueous dissolution medium at the oil-water interface, respectively. P is the 
partition coefficient between oily phase and dissolution medium. Both Ctoil and Ctaq-inter  
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Figure 3-5. The effect of cylinder diameter on the release amount of 
buprenorphine in CIB dissolution model. 
 
D is the cylinder diameter. 
n =3. 
Data are presented as mean ± SD (g). 
Tested formulation was formulation 3-1c. 
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are the variables, but the ratio P is a constant. The partition coefficient of the drug 
between oily vehicle and dissolution medium is calculated by measuring the drug 
concentration in two phases at equilibrium state. Based on the assumption and the 
concept of Whitney-Noyes equation, the overall drug release in this dissolution model 
can be calculated from Equation 3-9. 
 
 
3.3.2.1. Derivation of mathematical Equation 3-9 
 
Noyes-Whitney equation describes the drug release from the solid dosage form, 
while drug release from the oily vehicle is more complicated. In the solid dosage form, 
Noyes-Whitney equation shows that concentration gradient is the driving force for drug 
to diffuse into the aqueous phase. In the sink condition, the drug concentration in the 
aqueous phase may be ignored, otherwise it can’t. Drug release from oily phase to 
aqueous phase in CIB dissolution model is the diffusion-controlled process and can be 
illustrated as following.  
 
 
 
where C0t, C1t, and C2t represent drug concentration in oily phase, at the interface, and in 
the bulk aqueous phase at different time points. 
 
According to aforementioned assumption, drug molecules in the oily vehicle 
diffuse into the aqueous dissolution medium and the kinetic equilibrium can be achieved 
instantly at the interface and the drug concentration at the interface between the oily 
vehicle and dissolution medium can be calculated by Equations 3-1 and 3-10.  
 
During the drug release process, oily vehicle in the formulation could (1) dissolve 
or (2) partly dissolve in the aqueous phase. Both conditions were considered in the 
development of the drug mechanism. 
 
 
tC0  
tC1  
tC2  
h 
Oily 
phase 
Aqueous 
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3.3.2.1.1. Oily phase doesn’t dissolve in aqueous phase 
 
Under the sink condition 
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where C0 and V0 are constants and represent initial drug concentration and initial volume 
in the oily phase. Mt represents the amount of drug at different time pints in aqueous 
phase. 
 
After solving the differential equation, following Equation 3-9 was derived to 
describe the drug release from insoluble oily vehicle to the aqueous solution in the sink 
condition. 
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where Va is the volume of the aqueous phase. 
 
After solving the differential equation, Equation 3-11 is obtained. 
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The V0 is usually 0.2 mL and Va is 900 mL in this study. It indicates when P-1Va 
>> V0 or P is less than 4500, Equation 3-11 can be simplified to Equation 3-9. 
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3.3.2.1.2. Oily phase partially dissolves in aqueous phase 
 
If oily phase partially dissolves in aqueous phase, V0 will not be the constant and 
the release of the oily vehicle will affect the release of drug. The release of oil and drug 
molecules is considered as independent. The release of oil will decrease the volume of 
oily vehicle and increase the drug concentration in the oily phase. Therefore the drug 
release rate will increase. According to the Noyes-Whitney equation, the release of oily 
vehicle can be described as: 
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where Cs’, C2’ represent saturated concentration of oil and concentration of oil in the 
aqueous phase, respectively. Mt’ represents the amount of oily vehicle at different time in 
aqueous phase. D’, h’ and S’ represent diffusion coefficient, the length of diffusion layer, 
and oil-water interface area of the oil vehicle. 
 
Then the release of drug molecules can be described as: 
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where V0t is the volume of oily phase at different points. 
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where d’ is the density of oil and Mtotal’ represents the total amount of oily vehicle.  
 
After dissolving Equation 3-12, Equation 3-13 can be obtained. 
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If the oily vehicle is insoluble (Cs’ ≈ 0) or partly soluble (Mtotal’ >> VaCs’) in the 
aqueous phase, Equation 3-13 can be simplified to the following Equation 3-9. 
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Oily vehicles usually are insoluble in the aqueous phase and the tested oily 
vehicle in this study, TBC, is insoluble in water. Although the increasing amount of 
surfactant or cosolvent and the adjustment of pH in the dissolution medium could 
increase the solubility of oily vehicle in the medium. But until the majority of the oily 
vehicle is insoluble in the aqueous phase, Equation 3-9 can be applied. Therefore, 
Equation 3-9 is used to describe the drug release from TBC formulations in this study. 
 
 
3.3.2.2. Verification of mathematical equation 
 
There are seven parameters in Equation 3-9. Amongst them, Mt is the variable 
and can be measured by HPLC. Partition coefficient, P, can be calculated by measuring 
drug concentration between dissolution medium and oily vehicle at equilibrium state. K 
is related to the diffusion coefficient, D, and the length of diffusion layer, h. For the given 
formulation and dissolution medium, the P and K could be considered as the constant. In 
order to verify this equation, the rest parameters, C0, V0, and/or S, were challenged.  The 
verification procedures of Equation 3-9 were performed as follows. 
 
Step 1. Run the dissolution test and calculate K for the given oily vehicle and 
dissolution medium. 
 
1. Measure the partition coefficient P between oily vehicle and dissolution 
medium at equilibrium state 
2. Select the cylinder and calculate the S of the cylinder cavity 
3. Prepare the oily formulation and calculate the initial drug concentration C0  
4. Weigh the formulation after loading it into the cavity of the cylinder and then 
calculate the formulation volume V0. 
5. Run the dissolution test and measure the released drug amount at 
predetermined time points, Mt. 
6. Calculate the K from the slope Kapp by plotting Ln(C0V0)-Ln(C0V0-Mt) versus 
time. 
 
Step 2. A new in vitro test was conducted using the same oily vehicle, dissolution 
medium, and other dissolution conditions as the initial dissolution study in step 1. Since 
the dissolution conditions didn’t change, the initial and new dissolution study should 
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share the same K value which was calculated from initial dissolution study. From the 
calculated K, the amount drug release could be predicted by challenging variables, C0, 
V0, and/or S, and calculated by Equation 3-14 derived from Equation 3-9. The predicted 
results were compared with the experimental data. The variance between experimental 
and predicted data was compared by calculating f1 and f2 values. 
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  (Eq. 3-14) 
 
The in vitro release studies were carried out at 37 ± 0.5 °C using the CIB model 
and the dissolution medium of 10% (v/v) iso-propyl alcohol (IPA) in PBS at pH 7.4 was 
used in this study. The distance between the top of the basket and the bottom of paddle 
was set at 2 cm. The loading amount of the formulation was about 210 ± 5 mg. The 
volume of dissolution medium is 900 mL. Other parameters, such as cylinder # and 
paddle speed, varied in studies for different purposes and will be specified in the each 
section.  
 
 
3.3.2.2.1. Effect of different surface area (S) 
 
In order to verify the effect of different surface area (S) in the equation, TBC 
formulation 3-1c was tested in this study and cylinder #2 (cylinder diameter 15.0 mm) 
was used in the initial in vitro dissolution study to calculate K. From this calculated K, 
the amount of drug release from cylinder #1 and #3 with different S could be predicted. 
The predicted drug release data from calculated K was compared to the experimental data 
generated from cylinder #1 (cylinder diameter 12.5 mm) and #3 (cylinder diameter 17.5 
mm).  The paddle speed was set at 100 rpm. The drug concentration at different time 
points was detected by HPLC method.  
 
By plotting Ln(C0V0)-Ln(C0V0-Mt) vs. time (Figure 3-6a), the slope Kapp is 
0.0463 day-1. The measure P between TBC and dissolution medium is 4549. So 
calculated K is 0.64 cm·hr-1. Cylinder #1 and #3 were used to test real time drug release 
and compared to the predicted drug release data (Figure 3-6b1 and 3-6b2). In terms of 
percentage release, the dissimilarity/similarity factor f1 and f2 values were 11.3/95.3 for 
cylinder #1 and 7.2/92.8 for cylinder #3. The results indicate that the Equation 3-9 can 
be applied to predict the drug release from tested oily vehicle by changing the cylinder 
with different diameter. 
 
 
3.3.2.2.2. Effect of changing several parameters simultaneously 
 
Equation is verified only when the all the parameters in it can be challenged. In 
order to test the effect of changing several parameters simultaneously to the Equation   
3-9, formulation 3-1a with the concentration of 3.2 mg/mL (0.3%, w/w) was tested in the 
initial dissolution study to calculate K. The loading amount was about 210 ± 5 mg and 
the cylinder #5 with the diameter 15 mm was used. The drug concentration at different  
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Figure 3-6. (a) The release profile of buprenorphine from formulation 3-1c, and 
predicted data and experimental data generated from (b1) cylinder #1 and (b2) #3. 
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time points was detected by HPLC method. By plotting Ln(C0V0)-Ln(C0V0-Mt) vs. time 
(Figure 3-7a), the slope Kapp is 0.056 day-1. The measured P is 4549 between TBC and 
dissolution medium. The calculated K is 1.24 cm·hr-1. From the calculated K, the amount 
drug release was predicted using the Equation 3-9 by changing the parameter(s) of C0, 
V0, C0 &V0, C0 & S, and C0, V0 & S, simultaneously. 
 
The effect of C0 was explored by predicting the drug release from the 
formulations 3-1c and 3-1d with different concentration (1.5% and 3%). Figure 3-7b1 
and 3-7b2 showed the predicted drug release amount by time and the experimental data. 
In terms of percentage release, the f2/f1 values were 83.5/14 and 86.9/11.9 for 
formulation 3-1c and 3-1d, respectively.  
 
The effect of C0 and V0 simultaneously was explored by predicting the drug 
release from the formulation 3-1d with the drug concentration (3%) and loading volume 
(~ 0.27 mL). Figure 3-7c showed the predicted drug release amount by time and the 
experimental data. In terms of percentage release, the f2/f1 values were 86.8/18.2.    
 
Figure 3-7b2 and 3-7c also showed the effect of V0 (~ 0.2 and 0.27 mL, 
respectively) with the constant drug concentration (3%) and fixed surface area. 
 
The effect of C0 and S simultaneously was explored by predicting the drug release 
from the formulation 3-1c with different drug concentration (1.5%) in cylinder #6 with 
the diameter of 17.5 mm. Figure 3-7d showed the predicted drug release amount by time 
and the experimental data. In terms of percentage release, the f2/f1 values were 88.5/7.2.   
 
The effect of C0, V0 and S simultaneously was explored by predicting the drug 
release from the formulation 3-1c with the drug concentration (1.5%), loading volume 
(0.26 mL), and the cylinder #6 with the different diameter of 17.5 mm. Figure 3-7e 
showed the predicted drug release amount by time and the experimental data. In terms of 
percentage release, the f2/f1 values were 88.9/8.8.   
 
According to the FDA guidance,111 two dissolution profiles are declared 
equivalence if f1 values are between 0 and 15 and f2 value are between 50 and 100. From 
aforementioned results, after changing several parameters simultaneously, there is no 
significant difference between experimental and predicted data. Therefore Equation 3-9 
can give a good prediction of the amount of drug release for the tested formulation and it 
is expected that Equation 3-9 can be used to describe the drug release process in CIB 
dissolution system.  
 
 
3.3.3. IVIVC 
 
Level A IVIVC represents a point-to-point relationship between in vitro 
dissolution and the in vivo drug absorption from the tested dosage form. Although there 
is the lack of the regulatory IVIVC guidance for parenterals, it is believed that the FDA 
principles of the IVIVC for modified solid dosage form can be used for parenterals.107 
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Figure 3-7. The buprenorphine release profile and the comparison of 
experimental data and predicted data at different conditions. 
 
(a) The initial buprenorphine release profile from formulation 3-1a with concentration of 
0.3% and loading volume of ~0.2 mL in the cylinder #5 (diameter: 15 mm). 
(b.1) Changing C0 to 1.5%. 
(b.2) Changing C0 to 3%. 
(c) Changing C0 to 3% and V0 to 0.27 mL. 
(d) Changing C0 to 1.5% and using cylinder #6 (diameter: 17.5 mm). 
(e) Changing C0 to 1.5%, V0 to 0.26 mL and using cylinder #6 (diameter: 17.5 mm). 
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For a reasonable IVIVC, FDA guidance108 states that two or more formulations with 
different release rates should be used to demonstrate the IVIVC relationship and the 
absolute percentage prediction errors (PE%) of Cmax and AUC should be less than 15% 
for each formulation and the average number are less than 10%. If these criteria are not 
met, evaluation of external predictability of the IVIVC should be performed. 
 
The in vivo drug release data of formulation 3-1b and 3-2 in rat studies were used 
to develop Level A IVIVC. After intravenously administration of buprenorphine solution 
at a dose of 0.05 mg/kg, the average values of K10, K12, K21, V1, and AUC of six SD rats 
were 1.21 hr-1, 0.82 hr-1, 0.94 hr-1, 764 mL, and 13.2 hr·ng·mL-1 respectively. After 
subcutaneous injection of the buprenorphine saline solution at the same dose, the AUC 
with the value of 18.4 hr·ng·mL-1 was calculated. After normalizing by dose, the 
calculated bioavailability was 116%. The value is more than 100% and this could be 
caused by the variance of individual rat. The value 100% of bioavailability was used in 
the following calculation. Figure 3-8a shows in vivo drug plasma concentration profile 
of formulation 3-1b and 3-2 prepared with TBC and ATBC, respectively. The figure 
indicates that drug release rate is different for the two formulations. The drug release 
occurred in a controlled manner for two weeks. Buprenorphine solution prepared with 
TBC was able to achieve average Cmax of 8.5 ng/mL at 6 hours at the dose of 3 mg/kg 
and maintain the average plasma concentrations above 0.96 ng/mL for 336 hours (14 
days). Buprenorphine solution prepared with ATBC was able to achieve average Cmax of 
11.15 ng/mL at 12 hours at the same dose and maintain the average plasma 
concentrations above 1 ng/mL for at least 192 hours (8 days). Also the drug release rate 
of Formulation 3-2 was higher than that of Formulation 3-1b. 
 
The IV plasma profile showed the characters of the distribution and elimination 
phases, Therefore the Loo-Reigelman method developed from two compartment model 
was used to calculate the fraction of drug absorbed in vivo (Fa). Figure 3-8b shows the 
in vivo cumulative drug releases after subcutaneous injection of formulation 3-1b and  
3-2. The ATBC and TBC formulation displayed different absorption rate. The drug 
release from ATBC formulation was faster than that from TBC formulation. Figure 3-8c 
indicates a good linear correlation between Ln[C0V0/(C0V0-Mt)] verse time with R2 = 
0.9943 for TBC formulation and 0.9979 for ATBC formulation, respectively. It can be 
speculated that Equation 3-8 also describes the in vivo drug release after subcutaneous 
injection of formulation 3-1b and 3-2.  
 
In vitro dissolution study was conducted with the same formulations (Figure  
3-9a). The loading volume of the oily formulation was the same with that in in vivo 
study. The principles of media selection will be discussed in Chapter 4. Since the real 
time release of tested formulations will last for two weeks, accelerated conditions were 
applied in dissolution study with the time scale factor of 2. The dissolution medium of 
15% of n- propyl alcohol in PBS (v/v) with 0.15% SDS at pH6.0 was selected and the 
paddle speed was set at 100 rpm. A good linear correlation between Ln[C0V0/(C0V0-Mt)] 
and time was also obtained with R2 = 0.9966 for TBC formulation and R2 = 0.9991 for 
ATBC formulation, respectively (Figure 3-9b). The slopes of the in vivo data were 
determined to be about 0.0117 hr-1and 0.00718 hr-1 (Figure 3-8c) for the “fast” and  
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Figure 3-8. In vivo data process of formulation 3-1b and 3-2 after subcutaneous 
injection in rats for IVIVC development. 
 
(a) Plasma concentration profile of buprenorphine. 
(b) In vivo cumulative drug release profile.  
(c) Relationship between Ln[C0V0/(C0V0-Mt)] and time after subcutaneous injection of 
formulation 3-1b and 3-2 prepared with different oily vehicles in rat study. 
Doses of in vivo studies were 3 mg/Kg. 
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Figure 3-9. In vitro data process of formulation 3-1b and 3-2 for IVIVC 
development. 
 
(a) In vitro drug release profiles. 
(b) Relationship between Ln[C0V0/(C0V0-Mt)] and time. 
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“slow” release dosage forms, corresponding to the in vitro release slopes of 0.014 hr-1and 
0.0098 hr-1 (Figure 3-9b) for the relative formulations. These indicated that the 
mechanism of in vitro drug release mimics those of in vivo drug absorption and there 
could be a point to point correlation between in vivo and in vitro data. 
 
A level A in-vitro in-vivo correlation was investigated using the percent of drug 
dissolved and the percent of drug absorbed data for the slow and fast release 
formulations. A good linear regression relationship was observed between the percent 
dissolved in the dissolution testing and the percent absorbed for the combined data of the 
two formulations (y=1.051x-0.7036, R2 = 0.9918, Figure 3-10).  
 
The validation of the correlation was performed by determining how well the 
IVIVC models could predict the rate and extent of buprenorphine absorption as 
characterized by Cmax and AUC. The IVIVC model predicted drug plasma concentration 
versus time profiles of formulation 3-1b and 3-2 were compared to the experimental data 
points. The observed and predicted Cmax, AUC and the percentage errors of internal 
validation were listed in Table 3-2. The absolute PE% of Cmax and AUC are less than 
15% for each formulation and the average number are less than 10%, which fit the FDA 
requirement. 
 
Although it is not required by FDA, formulation 3-3a was used to perform 
external validation of the IVIVC model. The dissolution medium and conditions used in 
internal validation were applied to perform in vitro dissolution study. Figure 3-11 shows 
in vitro drug release profile of formulation 3-3a. It indicates that drug release rate and 
release profile of formulation 3-3a are different with those of formulation 3-1b and 3-2 
(Figure 3-8b). The IVIVC developed from formulations 3-1b and 3-2 was used to predict 
the plasma concentrations of the new formulation. Table 3-3 indicates the 
actual/predicted Cmax and AUC are 6.91/7.73 ng mL-1 and 1138.6/1151.4 hr•ng mL-1, 
respectively. The absolute PE% of Cmax and AUC are less than 15%. The fraction of 
drug absorbed in vivo was also calculated by Loo-Reigelman method (Figure 3-12). In 
this case, the fraction of drug absorb in vivo and percentage of drug released in vitro also 
showed a good linear relationship (Figure 3-13, R2 = 0.9922).   
 
 
3.4. Conclusions 
 
 To date it is still a challenge to develop a Level A IVIVC for parenteral products 
and there is no standard in vitro dissolution model with the character of Level A IVIVC 
for oily formulations. The cylinder-in-basket (CIB) model was designed based on the 
drug absorption mechanism after subcutaneous injection. A mathematical equation, 
Equation 3-9, was derived to improve the understanding of the diffusion controlled drug 
release mechanism involved in the CIB model. The equation was verified by challenging 
the parameters in the equation and comparing the experimental drug release data with 
predicted data. According to the equation, in vitro drug release follows the 1st order, and 
the equation could also describe the in vivo drug release mechanism after subcutaneous  
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Figure 3-10. IVIVC model linear regression plots of percent absorbed versus 
percent released for formulation 3-1b and 3-2. 
 
%Abs = 1.051·%Released - 0.7036, R2 = 0.9918. 
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Table 3-2. Internal predictability of the IVIVC model. 
 
Cmax (ng/mL)  AUC (hr*ng/mL) Vehicle Formulation 
Observed Predicted PE(%)  Observed Predicted PE(%) 
TBC 3-1b 8.44 8.85 4.9  1179.2 1189.84 0.9 
ATBC 3-2 11.10 9.70 -12.6  1307.2 1262.50 -3.4 
 
 
 
 
Table 3-3. External predictability of the IVIVC model. 
 
Cmax (ng/mL)  AUC (hr*ng/mL) Vehicle Formulation 
Observed Predicted PE(%)  Observed Predicted PE(%) 
TEC:ATEC:TBC 
(1:1:1, v/v/v) 3-3a 6.91 7.73 11.87  1138.6 1151.425 1.1 
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Figure 3-11. In vitro drug release of formulation 3-3a. 
 
n = 3. 
Data are presented as mean ± SD. 
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Figure 3-12. (a) Plasma concentration profile of buprenorphine, and (b) in vivo 
cumulative drug release profile after s.c. injection of formulation 3-3a in rats. 
 
n = 4. 
Data are presented as mean ± SD. 
Dose of in vivo study is 3 mg/Kg. 
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Figure 3-13. Linear regression of percent absorbed versus percent released for 
formulation 3-3a. 
 
 
 
 82 
injection in rat studies. The results of linear relationship between Fa and Fdiss and 
validation results suggested that Level A IVIVC was developed for the tested oily 
formations using the CIB model. This is the first time there is an in vitro dissolution 
system with the character of level A IVIVC for oily formulations. It also has the potential 
to be applied to other parenteral dosage forms if they share the same drug release 
mechanism.  The Equation 3-9 was derived from diffusion controlled drug release 
mechanism and some assumptions were made during the derivation. Therefore all these 
should be considered if CIB dissolution model was applied to other dosage forms.  In 
addition, CIB devices were modified based on the USP apparatus I & II. Therefore it is 
easy to be applied in the dissolution labs since USP apparatus I & II are the most popular 
dissolution devices and available in the labs. This novel in vitro dissolution model may 
contribute as a valuable tool for formulation development, bioequivalence testing, and as 
an aid in setting dissolution specifications in QC of parenteral products. 
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CHAPTER 4.    APPLICATION OF A NOVEL IN VITRO DISSOLUTION 
MODEL: A RATIONAL METHOD TO SELECT THE DISSOLUTION 
CONDITIONS IN AN ACCELERATED DISSOLUTION STUDY 
 
 
4.1. Introduction 
 
Unlike extended release (ER) solid dosage forms, ER parenterals were usually 
designed to release drug for days, weeks, months, and even years. The real-time 
dissolution analysis of ER parenteral formulations is time-consuming and sometimes 
impractical. Accelerated in vitro release study can correlate short-time release data with 
real-time release data in order to predict real-time drug release and minimize the potential 
problems in the real-time release studies, such as stability. Therefore, accelerated in vitro 
release testing methods are important and helpful for quality control of the product and 
ER parenteral formulation development.  
 
Usually the problem for accelerated study is that accelerated methods may not be 
bio-relevant and often change not only the drug release rate but also the mechanism of 
release.70,103 This change may not affect quality control and formulation development of 
the ER parenterals, but it could increase the difficulty to establish Level A in vitro-in vivo 
correction (IVIVC). In order to increase drug release rate without changing the release 
mechanism in the accelerated study, it is very important to choose suitable in vitro 
dissolution model and conditions, and understand how the variables affect the drug 
release mechanism. 
 
Temperature, solvent, pH, surfactants, agitation rate, etc106,114 have been 
successfully applied in the accelerated study to change the drug release rate, but it is 
always a challenge, especially for the ER parenterals, to explore the rational method to 
find the desired dissolution conditions for in vitro accelerated testing in a short-time 
period. Ideally, the accelerated in vitro study should be bio-relevant and correlate with 
the in vivo study, especially if the accelerated method is to be used as a surrogate for in 
vivo studies.70 In addition, the ideal accelerated condition should only increase the drug 
release rate without changing the release mechanism. The Cylinder-in-Basket (CIB) 
method has shown bio-relevant with the character of level A IVIVC and discussed in 
Chapter 3. The drug release mechanism of CIB model follows the first-order kinetic and 
Equation 4-1 is developed to describe in vitro drug release in this model. Equation 4-2 
is derived from Equation 4-1 and is used to describe the in vivo drug release of tested 
formulations after subcutaneous injection.  
 
For in vitro:  
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For in vivo:  
 
tKMMLnLnM appttotaltotal  )(   (Eq. 4-2) 
 
where C0 and V0 represent initial drug concentration and volume of loaded formulation; 
Mt represents the amount of drug at different time in aqueous phase in in vitro studies and 
the amount of drug released at different time point in in vivo studies; D, h and S represent 
diffusion coefficient, the length of diffusion layer, and oil-water interface area; the K is 
the ratio of D divided by h and Kapp  is the apparent rate constant; Mtotal represent the total 
amount of drug released at different time point in in vivo studies. 
 
Theoretically, drug release rate, Kapp, should be altered without changing the 
release mechanism. Kapp is related to K, S, V0 and P. Therefore it is possible to find a 
rational method to select dissolution medium based on the information of Kapp. The 
purpose of this study is to apply CIB dissolution model in the accelerated study for 
parenterals and develop a rational method to select the accelerated dissolution condition 
in a short time period. 
 
 
4.2. Materials and Methods 
 
 
4.2.1. Materials 
 
Buprenorphine base was obtained from Diosynth Inc. (Morrisville, NC).  Tributyl 
citrate (TBC), and acetyltributyl citrate (ATBC) were obtained from Morflex, Inc. 
(Greensboro, NC).  
 
 
4.2.2. Analytical methodology - HPLC/Fluorescence analyses  
 
Validated HPLC method developed to quantitate buprenorphine in the samples 
obtained from in vitro studies was described in Chapter 2. Briefly, Discovery C-18 
column (2.1 x 100 mm) (Supelco, Bellefonte, PA) was used. The mobile phase was 
composed of a mixture of 51 mM KH2PO4 buffer and acetonitrile (ACN) (45:55, v/v) 
with the final pH 6.65 adjusted by 10N NaOH solution. The oven temperature was 40°C 
and the flow rate was 0.3 mL/min. The total run time was 6 minutes. Buprenorphine was 
detected with fluorescence detector at λExitation = 292 nm and λEmission = 350 nm.  
 
 
4.2.3. Dissolution method 
 
In vitro dissolution studies of buprenorphine ER formulations were tested in the 
cylinder-in-basket (CIB) dissolution model.115 The oily formulation was loaded into the 
cavity of the cylinder with the diameter of 15 mm and the height of 24.6 mm. After 
covering with the 40-mesh United States Pharmacopeia (USP) basket, the cylinder-in-
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basket kit was transferred to 1-Liter vessel. The 900 mL dissolution medium was 
carefully loaded into the vessel at the rate of 7 mL/sec by modified Hanson Media Mate 
(Hanson Research Corp.). Different dissolution media were tested for different purposes 
and the content of the media will be specified in the following discussion section. The 
USP paddle was then loaded on the top of the basket with the distance of 2 cm between 
paddle and basket. The vessels were covered with a lid and tightened with laboratory 
para-film in order to avoid evaporation of the medium. The experiments were conducted 
in triplet. During the experiment, 1 mL of samples was withdrawn from bulk dissolution 
medium at predetermined time points by AutoPlus Autosampler (Hanson Research 
Corp.). After sampling, 1 mL blank dissolution medium was refilled into the bulk 
dissolution medium. Drug content in the samples was measured by HPLC method. The 
stability studies were also performed in triplet and conducted at 25 ± 0.5 °C and 40 ± 0.5 
°C ovens for tested formulations in all tested dissolution media. The results showed that 
buprenorphine was stable in the all dissolution media at 40 ± 0.5 °C for the length of 
tested dissolution time. 
 
The amount of drug release in percentage from the oily solutions was calculated 
according to Equation 4-2. 
 
 %100% 1
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
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
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
total
n
n
nbns
M
CVCV
released  (Eq. 4-2)
 
 
where Vs is the sampling volume (1 mL in this study) at different time points and Vb is 
the volume of total dissolution medium. Cn and Cn-1 represent the drug concentration in 
sample n and n-1.  Mtotal is the total amount of drug in the tested formulation. 
 
 
4.2.4. Formulation preparation 
 
In this study, buprenorphine ER oily formulations were used as the model system 
and the formulation preparation was described as following. An appropriate amount of 
buprenorphine powder was accurately weighed and dispersed into an appropriate amount 
of solvent (Table 4-1) in 20 mL glass scintillation vials. The subsequent suspension was 
sonicated under 25ºC until all drug powder was dissolved. The drug concentration was 
verified by HPLC method. The formulation 4-1 and 4-2 have the same composition as 
formulation 3-2 and 3-1b, respectively. 
 
 
4.2.5. Partition coefficients 
 
The partition coefficient testing of buprenorphine between the oily vehicles and 
dissolution media was performed in triplicate. Solutions of drug in aqueous phase-
saturated oily vehicles were allowed to equilibrate with the oil phase-saturated aqueous 
buffers in the incubator at 100 rpm and 37 ± 0.5°C for at least 48 hr. Drug concentrations  
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Table 4-1. Formulations tested in the method development of accelerated 
dissolution study. 
 
Concentration of Buprenorphine in Solvent Formulation Solvent 
% (w/w) 
4-1 ATBC 0.5 
4-2 TBC 0.5 
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in the aqueous phase and oily phase were determined by HPLC method.  The partition 
coefficients were calculated according to Equation 3-1.   
    
aq
oil
C
CP   (Eq. 3-1)
 
 
where Coil and Caq represent the drug concentration in the oil and the aqueous phase at the 
equilibrium state, respectively.  
 
 
4.3. Results and Discussion 
 
Dissolution temperature and medium are two major conditions altered in the 
accelerated in vitro study. Dr. Burgess stated that elevated temperature in accelerated 
release testing was not suitable for PLGA microsphere systems in which release 
mechanism was diffusion controlled.116 It is speculated that elevated temperature may not 
be suitable for oily formulation in the accelerated study since it shared the same diffusion 
controlled release mechanism. Therefore one of the common parameters, temperature, 
was not selected to explore in this accelerated study. The altered pH and different amount 
of surfactant in the dissolution medium can accelerate the drug release rate and the effects 
of these parameters were explored in this study using CIB in vitro dissolution model.  
 
The pH effect of dissolution medium was firstly explored using USP buffer with 
pH 7.4, 6.8, 6.0 and 5.0. The release of buprenorphine from formulation 4-1 and 4-2 in 
different oily vehicles, ATBC and TBC, was tested. The cylinder with the diameter of 15 
mm and the height of 24.6 mm was used in this study. Figure 4-1 shows the drug release 
effect of the dissolution medium with different pH. The partition coefficients between 
different oily phases and dissolution media were also tested and the results are listed in 
Table 4-2. Buprenorphine is a weak base. When pH of the dissolution media changed, 
the ionization extent of drug will change, therefore solubility of drug in the dissolution 
media and the partition coefficient between oily phase and media will also vary. When 
the pH of dissolution medium changed from 7.4 to 5, the drug release rate increases and 
the partition coefficient decreases. 
 
Equation 4-1 described the drug release in the USP phosphate buffer with the pH 
of 6, 6.8 and 7.4 and the linear relationship (R2 > 0.99, Table 4-2) was obtained after 
plotting Ln[C0V0/(C0V0-Mt)] versus time. This indicated when pH of the dissolution 
media changed from 7.4 to 6.0, the drug release could be described by the same equation 
and the release mechanism does not change. It followed 1st-order release for the tested 
formulations and could be applied in the accelerated studies since the release rate could 
be increased without changing the release mechanism. Unfortunately, good linear 
relationship was not observed when applying pH 5.0 USP neutralized phthalate buffer 
(R2 = 0.9603 for formulation 4-1; R2 = 0.948 for formulation 4-2). The reason could be 
that pH effect or the drug release behavior in phthalate buffer solution (USP buffer, pH 5) 
may be different with that in phosphate solutions (USP buffer, pH 6, 6.8 and 7.4). 
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Figure 4-1. In vitro drug release profiles from (a) formulation 4-1 and (b) 
formulation 4-2 in USP specified dissolution media at different pH. 
 
n =3. 
Data are presented as mean ± SD. 
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Table 4-2. Dissolution paddle speed, partition coefficient and calculated parameters in accelerated studies.  
 
Formulation 4-1 
 (Oily Phase: ATBC)  
Formulation 4-2  
(Oily Phase: TBC) 
K  Kapp K 
Dissolution Medium 
Paddle 
Speed 
(rpm) P Kapp (hr-1) R
2 
(cm/hr)  
P 
(hr-1) 
R2 
(cm/hr)
USP buffer pH 7.4  50 8992.7 ± 323.1 0.0010  0.9951 1.094   1953.9 ± 110.7 0.0008 0.9937  0.1853 
USP buffer pH 6.8  50 2129.1 ± 75.5  0.0034  0.9946 0.8806  564.5 ± 3.8 0.0029 0.9934  0.1941 
USP buffer pH 6.0  50 403.2 ± 26.9 0.0082  0.9913 0.4022  151.7 ± 12.7 0.005 0.9933  0.0773 
USP buffer pH 5.0  50 35.6 ± 1.6 0.1117  0.9603 NA   64.8 ± 2.1 0.0923 0.9480  NA 
PBS with 0.05% (w/v) SDS at pH 6  50 139.6 ± 29.5 0.0269  0.9910 0.4501  756.5 ± 35.2 0.0084 0.9901  0.7525 
PBS with 0.1% (w/v) SDS at pH 6  50 47.4 ± 1.6  0.0831  0.9938 0.4567  331.5 ± 8.5 0.0201 0.9997  0.769 
PBS with 0.8% (w/v) SDS at pH 6  50 2.5 ± 0.1   0.4019  0.8557 NA   16.1 ± 0.6 0.4679 0.9829  0.874 
PBS with 0.1% (w/v) SDS at pH 7.4  150 233.6 ± 7.2 0.0485  0.9994 1.34  3979.5 ± 89.0 0.0119 0.9978  5.43 
PBS with 0.2% (w/v) SDS at pH 7.4  150 43.1 ± 2.3 0.7732  0.9904 3.83  324.6 ± 5.5 0.0957 0.9940  3.53 
PBS with 0.8% (w/v) SDS at pH 7.4  150 28.9  ± 4.0 1.2097  0.9904 2.94   31.2 ± 3.3 0.6876 0.9997  2.45 
 
PBS: phosphate buffer saline solution 
NA: not accessed 
Kapp and R2 were obtained by plotting Ln[C0V0/(C0V0-Mt)] versus time and K was calculated from Equation 4-1. 
n =3. 
Data of partition coefficient (P) are presented as mean ± SD. 
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The ideal accelerated condition should increase drug release rate without 
changing the drug release mechanism. According to Equation 4-1, the apparent drug 
release rate, Kapp, is related with the parameters of K, S, V0 and P. Amongst four 
parameters, S and V0 are considered as the constant for the selected cylinder and loading 
volume. Diffusion transportation is affected by agitation, medium viscosity and medium 
temperature.117 Agitation could affect the thickness of diffusion layer, h. According to the 
Stokes-Einstein equation, D is related to solvent viscosity, temperature and solute 
molecule radius. For the given drug molecule, oily vehicle, dissolution medium, 
temperature and pressure, the D could be considered as the constant. The change of 
dissolution medium would simultaneously change h and P between oil phase and media, 
therefore the K value will vary. In the accelerated testing, temperature, dissolution 
medium, and/or agitation speed has to be the parameters used to accelerate the drug 
release rate. Both values of K and P will always vary simultaneously in these situations. 
It seems impractical to apply Equation 4-1 to select accelerated condition since none of 
the two variables, P and K, is the constant for different dissolution media.  
 
But the question is when altered dissolution medium is used to increase 
dissolution rate, such as pH or amount of surfactant in the medium, how does the K value 
vary? Table 4-2 lists the experimental K values for tested formulations in the dissolution 
medium with different pH. When pH is changed from 7.4 to 6.0, the P values decrease 
22.3 and 30.2 folds for two formulations, respectively, while the K values decrease 2.7 
and 2.4 folds, respectively. This indicates that the variance of P is much larger than that 
of K. Therefore, if the P values have just “slightly difference”, the variance of K value 
could be rounded and considered as a constant. If K can be considered as the constant, it 
gives the possibility to select dissolution medium with desired drug release rate just from 
tested P values between oily vehicles and dissolution media.  
 
The assumption, “if the P values have just slightly difference, the variance of K 
value could be rounded and considered as a constant”, is made here. When it is validated, 
it will be helpful to choose dissolution medium based on the P values in the accelerated 
study. The procedures (Figure 4-2) of selecting dissolution medium in accelerated 
studies were listed as following. 
 
1. Calculate slopereal-time. The CIB dissolution model displays the character of 
Level A IVIVC for the oily formulations. Therefore the in vivo fraction of drug 
absorbed (Fa) profiles were applied as the real-time in vitro dissolution release 
profiles since Level A IVIVC has been established for the tested 
formulations.115 Plot real-time in vivo release profile of long term sustained 
release oily formulation from in vivo data and calculate slopereal-time by plotting 
Ln[Mtotal/(Mtotal-Mt)] versus time. The value slopereal-time is calculated from in 
vivo data and considered as the real-time slope of in vitro release. 
2. Select time scale factor. 
3. Select the type of cylinder and calculate S. 
4. Decide the loading volume (V0) for in vitro testing. For IVIVC purpose, the 
recommended loading volume is to keep the same volume used for in vivo 
study. 
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Figure 4-2. The procedures of selecting dissolution medium in accelerated study. 
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5. Run the initial in vitro dissolution test using the CIB dissolution model and 
calculate the K value by plotting Ln[C0V0/(C0V0-Mt)] versus time. Since there 
is no information about the dissolution media, the initial dissolution can be 
selected based on the experience or other criteria.  
6. Calculate recommended P value according to the following Equation 4-6. 
7. Measure a series of P values by varying the conditions in the dissolution media. 
For example, select different amount of surfactant to increase the drug release 
rate. 
8. Select second dissolution medium based on the recommended P value and run 
second in vitro experiment to verify the results. 
9. Calculate new K value from second dissolution study by plotting 
Ln[C0V0/(C0V0-Mt)] versus time. If the ratio of P values between oil/initial 
medium and oil/second medium has significant difference or K values are not 
close to 1, the new K value can be used to calculate the recommended P and 
select third dissolution medium. Although third dissolution may be performed, 
it will be the last dissolution study since second dissolution study has narrow 
down the variance of K. 
 
Accelerated study should not change the drug release mechanism and ideally the 
drug release data in accelerated study can correlate with in vivo drug absorption data. 
With this assumption, in vivo fraction of drug absorbed (Fa) profile could be considered 
as the ideal real-time in vitro drug release profile. Unfortunately the IVIVC for 
parenterals is always the challenge. Chapter 2 demonstrated that novel cylinder-in-
basket (CIB) in vitro dissolution model has the character of level A IVIVC for parenteral 
oily formulations. So in this study in vivo drug absorption profiles of tested formulations 
were used as the real-time in vitro drug release dissolution profiles. All the in vitro 
dissolution data generated were then compared with the real-time in vitro dissolution 
profiles in this study and relationship between accelerated in vitro release data and real-
time release data were described by Equation 4-3. 
 
Slopein vitro = Slopereal-time· time scale factor = Slopein vivo· time scale factor (Eq. 4-3) 
 
The slopein vitro is calculated by plotting Ln[C0V0/(C0V0-Mt)] verse time using in 
vitro dissolution data and the slopein vitro (Kapp), coefficient of determination (R2) and K 
were listed in Table 4-2. The slope of the in vivo profile (Slopein vivo) by plotting 
Ln[Mtotal/(Mtotal-Mt)] verse time follows the first order kinetics and equals to the slopereal-
time when the time scale factor is one. In this study, the bioavailability of the tested 
formulations equals to 100% (chapter 2). Therefore Mtotal equals to the amount of drug 
injected.  
 
From Equation 4-1 and 4-3, parameters of K, time scale factor and P can be 
calculated by Equations 4-4, 4-5 and 4-6, respectively. 
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The following two cases will discuss how this rational method is applied to select 
dissolution medium in which desired drug release rate can achieve. 
 
 
4.3.1. Case studies 
 
 
4.3.1.1. Case 1 (Formulation 4-1, time scale factor = 7) 
 
 More than 90% of drug was released from formulation 4-1 within two weeks 
(Figure 3-9a). Chapter 3 discussed Level A IVIVC is exist in this dissolution model for 
the tested formulations. Therefore in vivo percentage of drug absorption of formulation 
4-1 (Figure 3-9b) is considered as the ideal in vitro drug release profile. In order to 
accelerate the in vitro drug release rate of the formulation, time scale factor 7 is applied 
and the whole process can be described by two steps.   
 
 Step 1: calculation of parameter K. In the preliminary study, the solubility of 
buprenorphine in the medium with either non-ionic (Tween 80; Span 80) or ionic 
(Sodium Dodecyl Sulfate, SDS) surfactant are tested. The solubility of buprenorphine in 
8% (v/v) Tween 80 in PBS at pH 7.4 and 8% Span 80 (v/v) in PBS at pH 7.4 are less than 
35 μg/mL, while the solubility of buprenorphine in PBS with 0.05% SDS (w/v) at pH 7.4 
is 43.8 μg/mL. In order to keep the sink condition, the solubility of the buprenorphine in 
the dissolution medium is desired to be more than 35 μg/mL. Higher amount of non-ionic 
surfactant may also cause larger variation and has less flexibility to adjust in the future 
study, so surfactant SDS is used in the study to increase the solubility and maintain the 
sink condition in this study. The experimental Kapp equals to 0.0269 hr-1 when the 
formulation 4-1 is diffused into the medium of PBS with 0.05% (w/v) SDS at pH 6 
(Table 4-2). The cylinder with the diameter of 15 mm was used in this study and the 
loading volume (V0) of 0.2 mL was kept the same with the in vivo study. The 
experimental P equals to 139.6. Therefore, useful parameter K can also be calculated and 
the value is 0.4501 cm/hr. 
 
 Step 2: dissolution medium selection based on tested P value. It is possible to 
select the medium with desired P and achieve the objective if all the parameters in 
Equation 4-6 are available. The aforementioned assumption is if the variance of P is 
ignorable, the K could be considered as a constant to anticipate the P of the desired 
dissolution medium. In this case, the calculated K is around 0.45 cm/hr and the calculated 
P value is 48.5 from Equation 4-6 with the time scale factor of 7. After testing a series of 
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partition coefficients between ATBC and PBS solution at pH 6 with different amount of 
SDS, the medium of PBS with 0.1% (w/v) SDS at pH 6 was selected to do further 
dissolution test since tested P is 47 which is very close to estimated value of 48.5. And 
the ratio 3.34 of two P values (139.6 / 41.7) is considered as the acceptable variance. The 
used cylinder has the diameter of 15 mm and the loading volume of 0.2 mL was kept the 
same with the in vivo study. Figure 4-3a indicates the experimental and real-time amount 
of drug release data. The x axis is the real-time divided by time scale factor. Figure 4-3b 
shows that the relationship between accelerated drug release data (%releasedin vitro (y) ) 
and real-time drug release data divided by time scale factor (%releasedreal-time (x)) can be 
described by the linear equation: y = 1.0509x+0.4309 (R2 = 0.9987). It indicates that the 
accelerated drug release amount of formulation 4-1 in CIB model can be predicted and a 
good IVIVC between in vivo drug release and accelerated experimental data is 
established. 
 
 
4.3.2.2. Case 2 (Formulation 4-2, time scale factor = 14) 
 
In vivo drug release of formulation 4-2 can also last two weeks (Figure 3-9a) and 
in vivo percentage of drug absorption of formulation 4-2 (Figure 3-9b) is considered as 
the ideal in vitro drug release profile. In order to accelerate the in vitro drug release rate 
of the formulation, time scale factor 14 is applied and the whole process can be described 
by two steps.   
 
Step 1: calculation of K. In order to validate aforementioned method, formulation 
4-2 was tested at different conditions. The first in vitro dissolution test was performed at 
150 rpm in the PBS medium with 0.1% (w/v) SDS at pH 7.4. The experimental P value 
of buprenorphine between TBC and dissolution medium is 3979.5. The cylinder with the 
diameter of 15 mm and the loading volume (V0) of 0.2 mL were kept the same with the in 
vivo study. After plotting Ln[C0V0/(C0V0-Mt)] verse time, the Kapp value is 0.0119 hr-1 
with R2 of 0.9978. Therefore the calculated K is 5.43 cm/hr (Table 4-2).   
 
Step 2: selection of dissolution medium based on tested P value. The sustained 
release formulation 4-2 can release more than 90% drug molecules in rats within 14 
days.115 According to Equation 4-2, the slopein vivo of the formulation is 0.00718 hr-1. 
When time scale factor 14 is applied, the recommended P is 479.74 calculated from 
Equation 4-6. After testing a series of partition coefficients between TBC and PBS 
solution at pH 7.4 with different amount of SDS, the medium of PBS with 0.2% (w/v) 
SDS at pH 7.4 was selected to do further dissolution test since experimental P is 325 
which is close to estimated value. After analyzing the results from the dissolution study, 
K value from the new dissolution medium is calculated and the value is 3.53 which is not 
close to the initial K value of 5.43. The reason is that the change of the P values between 
the two dissolution media (from 3979.5 to 324.6) is beyond the limit of the assumption. 
Therefore the new recommended P should be calculated from the new K value, 3.53. The 
second recommended P is calculated from the new dissolution results and the P value is 
318 which is close to the previous tested value of 325. Otherwise, new dissolution 
medium should be selected based on the tested P values and the third dissolution test  
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Figure 4-3. Predicted drug release amount in accelerated study and IVIVC (case 
1).  
 
(a) Relationship of drug release amount between experimental and real-time data,  
(b) Relationship between % releasedin vitro (y) and % releasedreal-time (x) for formulation   
4-1.
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should be run and will give desired drug release profile. Figure 4-4a indicates the 
experimental and real-time amount of drug release. The x-axis is the dissolution time for 
in vitro study and real-time divided by time scale factor for in vivo study. Figure 4-4b 
shows that the linear equation, y = 0.9722x+4.8577 (R2 = 0.9931), can describe the 
relationship between drug release data in accelerated study (%releasedin vitro (y)) and real-
time drug release data (%releasedreal-time (x)) by applying time scale factor. It also 
indicates that a good IVIVC has been established and the drug release amount from 
formulation 4-2 at different time points in CIB model can be predicted.  
 
 
4.3.2. Discussion 
 
This study presented a rational method to select dissolution medium by testing 
just one or two in vitro dissolution experiments and measuring the partition coefficients 
between oily phase and different dissolution media. The initial in vitro dissolution 
experiment is to calculate K value of the initial dissolution system and obtain desired P 
value. The desired dissolution medium can be selected based on this P value. The above 
two cases indicate that the rational method has been developed and established to find the 
desired dissolution medium. 
 
The assumption of the method is “slightly difference” between the P values and K 
is considered as the constant by changing the content of the medium. In the 2nd case, the 
ratio of P values between oil/initial medium and oil/selected medium is 12.3 folds. The 
predicted P is 400.8 and the experimental P value between TBC and selected medium is 
325. The tested K values for the two media are close (4.56 vs 3.53, Table 4-2) but can’t 
be rounded. In this case, an additional dissolution experiment may be required to 
precisely predict P if ratio of P values between oil/initial medium and oil/selected 
medium is too high, or predicted accelerated data does not match the experimental data. It 
is difficult to define a constant value of P ratio to be the boundary so far. From author’s 
opinion, comparing K values may be more practical. If the ratio of K is close to 1, only 
one dissolution experiment can give a good or reasonable prediction. If not, extra 
attention should be paid and the calculated new K value from 2nd dissolution medium 
could be used to calculate new recommended K. The same procedure can be applied 
again to select dissolution medium. The new dissolution experiment actually refined the 
dissolution condition. General after maximum two dissolution tests the desired 
dissolution medium could be found. It is recommended the ratio of K values should 
always be examined. 
 
The real-time drug release from formulation 4-1 and 4-2 can last for 14 days. The 
aforementioned two cases gave the examples how to select the dissolution medium by a 
rational method to achieve drug release within 2 and 1 day, respectively, without 
changing the release mechanism. Ideally, shorter dissolution time, such as couple of 
hours, is preferred in accelerated study to provide the drug release information of the 14 
days sustained release formulation, and it will accelerate the formulation development 
and benefit QC. Theoretically it seems possible to achieve the objective since high 
amount of surfactant and/or low pH of dissolution medium could increase the drug 
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Figure 4-4. Predicted drug release amount in accelerated study and IVIVC (case 
2). 
 
(a) Relationship of drug release amount between experimental and real time data,  
(b) Relationship between % releasedin vitro (y) and % releasedreal-time (x) for formulation   
4-2. 
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release rate. Therefore drug release studies in phosphate buffer saline solutions (PBS) 
with high amount of surfactant at different pH were performed. The drug release of 
formulation 4-1 and 4-2 in PBS with 0.05%, 0.1% or 0.8% SDS (w/v) at pH 6 (50 rpm, 
Figure 4-5) and with 0.1, 0.2 or 0.8% SDS (w/v) at pH 7.4 (150 rpm, Figure 4-6) were 
invested. The experiments were performed in triplet. Figure 4-5 and 4-6 indicate that 
drug release rate increased with the high amount of surfactant in the tested formulations. 
Good linear relationship (R2 > 0.98, Table 4-2) was obtained in all dissolution media 
except in the PBS medium with 0.8% SDS (w/v) at pH 6 (R2 = 0.856 for formulation 4-
1). High amount of surfactant (0.8% SDS) in the dissolution medium not only 
dramatically increased the drug release rate, but also caused the large variance (SD, 
~20%) for certain formulation. During the procedure of loading dissolution medium, it is 
inevitable to cause some variance when two liquid phases are contacting to each other. 
Tiny variance between different vessels could be amplified when the drug release rate is 
significantly increased. This indicates that time scale factor should be carefully selected 
in order to reduce the variance. The faster release rate, the more variance may get. 
 
 
4.4. Conclusions 
 
Accelerated dissolution testing of buprenorphine oily sustained release 
formulations was attained by varying the pH and the amount of the surfactant in the 
dissolution medium in CIB dissolution model. This study demonstrated that dissolution 
of oily formulations in USP phosphate buffer with the pH from 6 to 7.4 followed 1st-order 
kinetic and could be described by Equation 4-1. A rational method (Figure 4-2) was 
developed in this study to select dissolution medium in the accelerated study according to 
the practical requirement. The two cases of 14-day sustained release formulations 
demonstrated how to utilize this method to select dissolution medium to achieve desired 
in vitro drug release rate without changing drug release mechanism. The proposed 
method   
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Figure 4-5. In vitro drug release from (a) formulation 4-1 and (b) formulation 4-2 
in phosphate buffer dissolution media with different amount of SDS at pH 6. 
 
n =3. 
Data are presented as mean ± SD. 
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Figure 4-6. In vitro drug release from (a) formulation 4-1 and (b) formulation 4-2 
in phosphate buffer dissolution media with different amount of SDS at pH 7.4. 
 
n =3. 
Data are presented as mean ± SD. 
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